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Abstract 
 
Clostridium difficile, a Gram-positive, anaerobic, spore producing bacillus is the leading cause of 
nosocomial diarrhea in health-care facilities. Its effect on patients can be detrimental to their 
recovery, sometimes leading to death; the catalyst to Clostridium difficile infection (CDI) is 
treatment by antibiotics. Focusing research on some of C. difficile’s genotypes and phenotypes, 
we hoped to be able to predict the severity and outcome of the infections based on the strain. C. 
difficile strains isolated from patients were characterized for the presence of the toxin genes and 
classified by ribotype. They were also tested for antibiotic susceptibility (E-test), toxin 
production levels, and microbial spore load in stools. The patients symptoms were evaluated to 
determine if there were any correlations between the genotypes/phenotypes and the infection 
outcomes. No significant correlation was found between the severity of disease and 
phenotypic/genotypic attributes of the C. difficile strain involved. Thus, other defining factors 
appear to affect patient prognosis such as the severity of the patients’ disease and the presence of 
co-morbidities. A key finding however was that 30% of the population was at risk of developing 
CDI due to carriage of toxigenic C. difficile. 
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1.0 Introduction 
Clostridium difficile (C. difficile) is a Gram-positive, obligate anaerobe, spore forming bacillus 
that has developed resistance to certain commonly used antibiotics [1], [2]. Its effect on the 
elderly and patients receiving antibiotic treatment can be detrimental to their recovery, 
sometimes leading to death [1], [3]. It is widely believed that the catalyst to the infection is 
treatment by antibiotics; antibiotics damage the gut’s microflora allowing for C. difficile 
colonization and release of its toxins [2]. This results in colonal epithelial cell death and an 
immune response that ultimately leads to colitis and diarrhea. C. difficile is the leading cause of 
nosocomial (health-care acquired) diarrhea and pseudomembranous colitis in the developed 
world [4]. Furthermore, the primary reservoirs for the organism are carriers who visit the health-
care facilities either for treatment, visit, or work [5]. Since the early 2000s, an increase in 
incidence of C. difficile infection (CDI) within hospitals has surged, the cause of which remains 
unknown [6]. Upon colonization in the colon, C. difficile excretes two enterotoxins, TcdA and 
TcdB, which enter intestinal epithelial cells and disrupt the cytoskeleton, resulting in cell lysis 
[7]. The activation of cell death and inflammatory pathways then result in the production of 
intestinal ulcers and diarrhea. 
 
1.1 C. difficile history 
C. difficile was first described by Hall and O’Toole in 1935 when they conducted a study to 
characterize  the intestinal microflora of newborn children [8]. C. difficile has since been found 
to be the leading cause of health-care acquired (nosocomial) infection in the developed world 
[9]. The infection has a wide range; however, the specific list of symptoms depends upon the 
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severity of the illness, and may include watery (sometimes bloody) stool, abdominal cramps, 
tenderness or distention, hypoalbuminemia, and the possible development of pseudomembranous 
colitis.  The infection can sometimes lead to death [9].   
 
Although the organism was first described in 1935, and pseudomembranous colitis first 
described by Finney in 1893, C. difficile infections did not get much recognition until the 1950s, 
when clindamycin became the preferred antibiotic of choice for use in treatment of anaerobic 
infections of the intestinal tract [10]. In 1973, Tedesco et al. conducted a study with 200 patients 
that were treated with clindamycin at St. Louis’ Barnes Hospital, of which 42 patients (21%) 
developed diarrhea, and 20 patients (10%) were discovered to have pseudomembranous colitis 
when endoscopy was performed [11]. Eight stool specimens from the study were stored and used 
in tests 5 years later; 4 of the stool samples were positive for C. difficile by culture and also 
contained toxins in the stool when tested with a cytotoxin assay. This study is considered to be 
one of the first documented cases of a C. difficile nosocomial outbreak [10]. The study of C. 
difficile has focused mostly in three areas in the period between Tedesco’s study in 1974 and the 
1990s: rodent models and their development of antibiotic-associated typhlitis, the anatomical 
study of pseudomembranous colitis, and the study of the organism itself. In 1978, C. difficile was 
recognized as a causative agent for pseudomembranous colitis, when two separate research 
groups isolated the organism from patients with pseudomembranous colitis. [12], [13]  
 
By the 1990s, it was understood that C. difficile infections arose in patients when treated by 
antibiotics, and various tests could be used to diagnose the infection. It was also known that 
treatment by metronidazole and vancomycin, the latter being the more effective yet more 
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expensive treatment, was effective in treating the infection [3]. However, a dramatic turn of 
events occurred in 2005, when over 2,000 fatalities were reported in Quebec in the largest C. 
difficile epidemic recorded. This was attributed to two factors.  One factor was the appearance of 
a newly discovered hypervirulent C. difficile strain. The hypervirulent strain was identified by 
the restriction endonuclease analysis (REA) group BI, North American pulse-field 
electrophoresis type 1 (NAP1), and polymerase chain reaction (PCR) ribotype 027 
(NAP1/BI/027).  The second factor was the overuse of antibiotics as a means of treatment [14]. 
After these events, efforts in the study of C. difficile were renewed and focused on understanding 
the workings of the organism, including methods of infection, colonization, toxin delivery, and 
sporulation (to name a few). 
 
1.2 Classification 
To better understand the changing epidemiology of C. difficile, researchers have used various 
types of molecular classification or “typing”. This helps monitor outbreaks, observe regional and 
global changes of the organism [15]. In the 1980s, phenotyping was much more common and the 
preferred technique was serotyping, and 15 serogroups were characterized. However, as 
technology became less expensive and more accessible, genotyping became the detection method 
of choice. Several typing methods emerged, namely pulse-field gel electrophoresis (PFGE), 
restriction endonuclease analysis (REA), and PCR ribotyping. Each technique offers its 
advantages, and each technique has its own nomenclature and classification scheme. PFGE for 
the purpose of C. difficile classification is named North American pulse-field, or NAP. This 
nomenclature is used in what is probably the most widely recognized C. difficile strain, the 
hypervirulent endemic strain NAP1/BI/027. NAP1 represents that PFGE classification, BI 
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represents the REA classification, and 027 is the ribotype classification. While any of these 
techniques can be used for in lab classification, PCR ribotyping has become a gold standard due 
to its high reproducibility, high sensitivity, high specificity, rapidity and ease of use [16].  
 
PCR ribotying is a fast, reliable, relatively inexpensive and highly reproducible technique that is 
commonly used in labs throughout the world. The 11 intergenic spacer regions (ISR) between 
the 16S and the 23S rRNA operons are highly polymorphic, and when amplified by PCR will 
produce bands of different sizes. Primers which contain a partial, exact sequence for the 16S and 
23S rRNA genes were designed by Bidet et al., at the end of the 1990s and are still in use today 
for ribotyping [16]. A forward primer anneals to bases 1482-1501 of the 16S rRNA gene, while 
the reverse primer anneals at bases 1-24 of the 23S rRNA to amplify the ISR found between 
these two genes. Resolving the bands by electrophoresis produce a “fingerprint” and it is this 
fingerprint that is used to group the C. difficile strains together. The bands range from 225bp to 
700bp, and there are as many bands as there are rRNA operons in the strains’ chromosomal 
DNA, usually between 7 and 10 bands [16]. As stated, this technique is highly reproducible, 
meaning that every time the test is repeated, the same fingerprint is generated making this 
technique a preferred one in the classification of C. difficile [16]. More than 300 ribotypes have 
been identified so far [17]. Sequence-based methods such as whole genome single nucleotide 
polymorphism typing are slowly starting to replace genotyping methods as they are able to 
discriminate between very closely related strains [15]. These methods are still quite expensive, 
but their pricing has dropped significantly over the last few years and will surely continue to do 
so; it appears as though they will become the new standard of testing in the future. 
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1.3 Colonization 
C. difficile is ubiquitous, found as a spore on many different surfaces, including foods, and in the 
intestinal tract of humans and animals [18]. While the spores are found on the surfaces, the most 
common mode of transmission is the fecal-oral route: people ingest the spores by touching 
contaminated surfaces and foods [9]. The infection that occurs due to this transmission can be 
divided into one of two categories: endogenous infections and exogenous infections. Endogenous 
infections originate from the carrier themselves, having the microorganism in their microflora, 
while exogenous infections occur via transmission from another source, such as a health-care 
worker or a contaminated individuals [19]. As mentioned earlier, the primary reservoir of the 
organism is the carriers who come to the health-care facilities for treatment. It is there that the 
spores gets transferred to the hands of the health-care works, who transport it from patient to 
patient [5]. However, not everyone who is infected with the spores will develop an infection; 
various factors will influence the likelihood an individual may have to develop an infection, 
these include older age (>65 years old), antibiotic usage, reduced immune response and other 
comorbidities [20].  
 
The spores are able to endure the harsh acid environment of the stomach, and make their way 
towards the anaerobic colon where they will be able to germinate [21]. Several studies have 
shown that bile salts such as sodium taurocholate help in the germination of C. difficile spores 
while in the bowel [22]. Furthermore, it was found that glycine can act as a co-factor in 
germination [22]. Spores germinate best at temperatures of 37
o
C, and a pH range between 6.5 to 
7.5 [23]. The spores germinate in the small intestine after exposure to bile salts and make their 
way with the aid of flagella and peristaltic intestinal movement to the colon where they will 
 6 
 
colonize. C. difficile multiplies in the colon; the gut mucosa facilitates the adherence to the 
epithelial cells [5]. Once C. difficile has colonized in the colon, it is then that it will start 
delivering the toxins that will cause the disease.  
 
1.4 Toxins 
Toxigenic C. difficile contains three toxins: toxin A (tcdA) and toxin B (tcdB), which are both 
found on the same locus, and a binary toxin (cdt). TcdA and TcdB have long been known to be 
the agents that cause pseudomembranous colitis, however in recent years research on CDT has 
revealed that it may also play a role in the infection [24]. 
 
1.4.1 TcdA and TcdB 
TcdA and TcdB are part of the large clostridial toxin (LCT) family, and share some homology to 
other toxins found in other Clostridia species, such as the Clostridium sordellii lethal toxin and 
the Clostridium novyi α-toxin [25]. TcdA and TcdB are both glucosyltransferases, and are some 
of the largest bacterial toxins with molecular weights of 308 kDa and 270 kDa, respectively [1], 
[2], [7], [26]. TcdA and TcdB are produced by C. difficile during the late exponential and 
stationary phases of bacterial growth [7]. The genes for both toxins are found on the C. difficile 
pathogenicity locus (PaLoc), a 19.6 kb region that is present, stable and conserved in toxigenic 
strains, while absent in the non-toxigenic strains [1], [7], [27]. 
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1.4.2 Pathogenicity Locus 
The PaLoc contains several different elements that are essential to the production and delivery of 
both toxins into the target cells; the locus is also very well described and understood [7]. The 
genes for Toxin A (tcdA) and Toxin B (tcdB) have large open reading frames (8133 nucleotides 
and 7098 nucleotides, respectively) [7]. The G+C content of both toxins is relatively low (28%), 
which is fairly similar to the rest of the C. difficile genome (29%). Furthermore, the two genes 
are highly homologous (66%), and taking into account the functional homology of the encoded 
proteins, it has been suggested that the presence of the two toxins is the result of an evolutionary 
gene duplication event [28].  
 
There are also 3 other open reading frames that are found on PaLoc: tcdC, tcdR and tcdE. tcdR, 
the positive regulator of the PaLoc found upstream of tcdB, is upregulated in coordination with 
tcdA and tcdB [7]. TcdR is used to activate gene transcription via an alternate RNA polymerase σ 
factor [29]. tcdC is found downstream in opposite direction to tcdA, and is highly expressed 
during the exponential growth phase [7]. Initially, it was observed that the expression of tcdC 
was upregulated while the expression of tcdA and tcdB were downregulated and vice-versa. It 
was found that tcdC is the negative regulator for the production of toxins on the PaLoc. tcdC 
codes for an anti-sigma factor that destabilizes the TcdR holoenzyme, which prevents the 
transcription of tcdA and tcdB [1]. A frameshift mutation is found at position 117 in 
NAP1/BI/027 hypervirulent strains and was thought to increase the virulence of the strain as it 
would be ineffective at downregulating toxin production during the growth phase of the 
organism [30]. There is, however, a conflicting study reporting that the overproduction of toxin 
occurs despite the mutation in the tcdC gene [31]. Finally, tcdE is found between tcdA and tcdB 
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genes and encodes for a holing-like protein that forms pores in the cell membrane of C. difficile 
to allow for the toxins to exit the microorganism [7]. The sequence of the tcdE gene and the 
structural conformation of TcdE protein suggest that TcdE is related to class I holins, also found 
in λ phages. These proteins are able to form pores in the cell membrane that would allow the 
large clostridial proteins through without causing cell death due to depolarization of the cell [32]. 
It is thought that TcdE has three transmembrane domains, including charged residues in the C 
terminus as well as a hydrophilic area in the N terminus that may help in avoiding depolarization 
of the cell while allowing for the toxins to exit the bacterial cell [33]. Figure 1a depicts the 
pathogenicity locus. 
 
A common practice when working with C. difficile is to amplify the tcdA and tcdB genes by PCR 
to confirm whether the strain contains both genes. This confirms whether the strain is tcdA+ and 
tcdB+, tcdA- and tcdB- (non-toxigenic), tcdA- and tcdB+ or tcdA+ and tcdB-. Furthermore, the 
primers for tcdA are also able to anneal to the smallest of the 3 deletions in the 3’ region of the 
gene, should it be present.   
 
1.4.3 Protein structure 
Like other members of the LCT family, the TcdA and TcdB proteins have 4 regions that are 
conserved among them: an N-terminus that has a biologically active glucosyltransferase domain, 
followed by a cysteine protease domain, a central region that is hydrophobic and thought to be 
implicated in the translocation of the protein into the cytosol, and finally a C-terminal domain 
containing combined repetitive oligopeptides (CROPs) involved in the highly specific cell-
surface receptor binding for entry into the epithelial cells [7], [25], [26]. The active toxin 
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function is located within the N-terminal domain; the first 500 amino acids (approximately) are 
cleaved off from the rest of the toxin protein by auto-proteolysis via the cysteine protease 
domain in the endosome and the truncated protein is translocated into the cytosol with the help of 
the hydrophobic domain of the toxin (Figure 1b), [26]. 
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a. 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
(a.) The pathogenicity locus is a 19.6 kb region that codes for the toxins TcdA, TcdB and three 
other open reading frames. tcdR is the positive regulator for the toxins, while tcdC is the negative 
regulator. tcdE is a putative holin protein that helps perforate C. difficile’s cell membrane to 
allow the toxin to exit. Adapted from Voth et al. (2005) [7] (b.) A simplified depiction of the 
three domain structure of the LCT as described by Voth et al. (2005). Represented are the 
enzymatic domain, hydrophobic translation domain and the receptor binding domain. Not shown 
is the cysteine protease domain, found between the enzymatic and hydrophobic translocation 
domain [7].   
Pathogenicity locus (19.6 kb) 
tcdR tcdA tcdE tcdB tcdC 
NH
2
 COOH 
Enzymatic domain -  
Glucosyltransferase 
activity 
Hydrophobic 
translocation domain 
Receptor-binding 
domain - CROPs 
Figure 1 - C. difficile pathogenicity locus and TcdB protein structure 
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1.4.4 Mechanism of action 
TcdA and TcdB work by glycosylating the Ras superfamily of GTPases. The Ras GTPases are 
small monomeric guanine nucleotide-binding proteins that act as molecular switches for various 
cellular signaling events.  The process of glucosylating proteins is irreversible, and inactivates 
the regulatory proteins, leading to disruption of vital signaling pathways that occur in the 
epithelial cells of the intestinal tract; this causes the breakdown of the cellular cytoskeleton [7], 
[34]. Before this process can happen, the toxins must first enter the epithelial cells; this occurs 
via receptor-mediated endocytosis [1]. The toxins also require the acidic endosome to activate a 
structural change and translocation into the cytosol of the epithelial cells [7]. The low pH (5.2-
6.0) of the endocytic vesicle is essential for the structural change that occurs to the toxin: the N-
terminal enzymatic domain of the toxin is cleaved from the rest of the toxin and the exposed 
hydrophobic portion of the protein forms a pore in the endocytic vesicle through which the 
activated portion of the toxin translocates into the cytosol [7], [35]. Once in the cytosol, both 
TcdA and TcdB are able to inactivate Rho, Rac and Cdc42, all part of the GTPase family in the 
intestinal epithelial cells. The functions of Rho include stress fiber formation, motility, and focal 
adhesion, while the functions of Rac and Cdc42 are related to the formation of lamellipodium 
and filopodium [7]. The toxins glycosylate the Rho protein by transferring a sugar moiety to Thr-
37 using UDP-glucose as a co-substrate. 
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Figure 2 shows the mechanism of action of both TcdA and TcdB in colon epithelial cells. First, 
the toxins must enter the cells through receptor-mediated endocytosis. In the low pH endocytic 
vesicle, the enzymatic domain of the toxin is cleaved from the protein structure, and the 
hydrophobic translocation domain of the toxin allows the enzymatic domain to go through the 
membrane of the vesicle into the cytoplasm of the cell. There, the active toxin glucosylates 
GTPase, which causes an inactivation of Rho, Rac and Cdc42. Adapted from Voth et al. (2005) 
[7]. 
 
 
UDP-glucose 
UDP 
Glucose 
GTPase 
GTPase 
GDP 
GDP 
Active 
Inactive 
Endosome 
pH 6.2-6.0 
TcdA or 
TcdB 
Receptor-mediated 
endocytosis 
Active toxin 
Actin 
Rho 
Rac 
Cdc42 
Epithelial tight 
junctions 
Figure 2 - TcdA and TcdB mechanism of action in colon epithelial cells 
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1.4.5 Impact on cell morphology 
Cells that have been treated with both TcdA and TcdB have shown a distinct change in the 
organization of their actin cytoskeleton. This is now seen as the hallmark of cellular intoxication 
by TcdA and TcdB. Rho (isoforms A, B and C) is a ubiquitous primary regulator of the actin 
skeleton in eukaryotic cells. Inactivation of the Ras GTPases by the toxins causes a loss of 
structural integrity; this is brought upon by the decline of F-actin levels, which are regulated by 
the Ras GTPases. Upon the loss of structural integrity, actin condensation occurs that leads to 
rounding of the cells, membrane blebbing, and eventually apoptosis [7]. This can occur quickly; 
it was shown by Qa’Dan et al. that TcdB could elicit cell rounding within 2 hours of treatment 
with TcdB, and that cell death occurs about 24 hours after treatment [36]. Furthermore, the 
permeability of the epithelial cells of the colon is increased due to TcdA inactivation of RhoA 
through protein kinase C; this may lead to the increase in inflammation observed in 
pseudomembranous colitis. The increase in polymorphonuclear cells found in the colonic 
epithelial layer may activate the expression of various chemokines, which also may serve as a 
mechanism that increases the inflammatory response observed in the colon [7].  Physiological 
events that occur in the affected area include inflammation due to increased epithelial 
permeability, neutrophilic infiltration, production of chemokines and cytokines, mast cell 
activation, and damage to the intestinal mucosa, all of which have a direct contribution to the 
development of pseudomembranous colitis [7]. 
 
1.4.6 Binary toxin (CDT) 
The binary toxin belongs to a family of binary ADP-ribosylating toxins, which include the 
Clostridium botulinum C2 toxin, the Clostridium perfringens iota toxin, and the Clostridium 
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spiroforme toxin. CDT is composed of two separate toxin components, hence the name binary: 
CDTa and CDTb. While the roles of TcdA and TcdB are well defined in CDI, CDT was 
overlooked until the early 2000s when the hypervirulent strain NAP1/BI/027 came into 
prevalence and it was observed that the CDT was present in that strain [2]. Since then, more 
focus has been given into the study of CDT to understand its role in CDI. The genes coding for 
CDT are found within the CDT locus (CdtLoc), a 6.2kbp region that encodes for cdtA, cdtB, and 
a regulatory protein cdtR. CDTLoc isn’t found in all C. difficile strains; however, when it is, it is 
either found whole or as a single truncated version. In C. difficile strains that do not contain the 
CdtLoc, a unique 68bp sequence is found in its place [2], [56]. CDTa is a 463 amino acid protein 
that contains 2 domains: an N-terminus with cell wall receptor binding properties, and a C-
terminus that is the enzymatic portion of the toxin with its ADP-ribosyltransferase activity. The 
second subunit of the toxin, CDTb, is 876 amino acids long, with 4 domains: domain I in the N-
terminus is an activation domain, domain II is responsible for membrane insertion and formation 
of pores, domain III is involved in oligomerization, and the C-terminal domain IV is involved in 
receptor binding [56].   CDTb is cleaved and activated to form heptamers while binding to the 
lipolysis stimulated lipoprotein receptor (LSR). The CDTa is recruited to the (CDTb)7-receptor 
complex. The assembled CDTb and CDTa enter cells via endocytic vesicles, and later, upon 
acidification of the endosomal vesicles, a pore is formed on the endosomal membrane by the 
CDTb component, allowing for only CDTa to be translocated into the cytosol. Once in the 
cytosol, CDTa ADP-ribosylates G-actin resulting in depolymerzation of F-actin [56]. This 
process of increased depolymerization of the actin skeleton also results in long microtubule-
induced membrane protrusions on the surface of the epithelial cells that increases the interaction 
surface of the cell for adherence of the colonizing C. difficile [56]. Knowledge of CDT is 
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overshadowed by the much more vast knowledge of TcdA and TcdB; however, recent studies 
suggest that CDT may be just as an important player as TcdA and TcdB in CDI (references). 
 
1.5 Sporulation 
In order for the infection to persist in the colon, and to disseminate to other hosts, C. difficile  
produces spores during the infection of the colon [37]. As mentioned before, the spores are 
passed along the feces-oral route, and a large amount of spores in the feces is crucial for this 
transmission to occur [18], [38]. Increased ability to form spores is thought to contribute to the 
spread and survival of the organism [39]. The sporulation mechanism of C. difficile has yet to be 
fully elucidated; sporulation mechanisms of other spore-forming organisms such as Bacillus 
subtilis and other Clostridial species are used as a model to facilitate the study [18], [37], [38], 
[40], [41]. Spo0A is the transcriptional regulator protein that regulates whether a vegetative cell 
will initiate sporulation. Factors that may activate the process of sporulation include lack of 
nutrients, exposure to oxygen, and some recent studies suggest that quorum sensing, a 
mechanism employed by bacteria using various stimuli (light, chemicals, nutrients) in response 
to population density to coordinate gene expression and behaviours, may even play a role in 
sporulation [42]. Several histidine kinases phosphorylate Spo0A that initiate the sporulation 
cycle [37]. Activation of Spo0A will in turn activate transcription of genes that code for RNA 
polymerase sigma factors that are specific to spore formation [37], [42].  
 
Prior to sporulation, the DNA is replicated so that there is a copy in the mother cell (the 
vegetative cell), and another copy in what is going to be the spore, known as the forespore.  In B. 
subtilis, Spo0A activates σF in the forespore, which then activates pro-σE in the mother cell along 
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with Spo0A. This will then activate σE in the mother cell, which together with σF in the forespore 
will activate σG in the forespore, followed by pro-σK activation to σK, both in the mother cell. 
However, in C. difficile, it was noted that the activation of sigma factors in the mother cell and 
the forespore do not depend on each other, with the exception of pro-σE activation in the mother 
cell by σF from the forespore and Spo0A [37]. After the activation of pro-σE in the mother cell, 
this will result in the activation of σE followed by σK. In the forespore, σG is activated by σF [37], 
[42].  
 
The spore is made of several different layers. In the center of the spore lies the spore core that 
contains the microorganism’s genetic material. Surrounding the spore coat is the inner 
membrane, whose phospholipid composition is very similar to vegetative bacteria and is not very 
permeable. The germ cell wall surrounding the inner membrane will become the C. difficile cell 
wall upon germination. The next layer is a thick cortex made of proteoglycans followed by an 
outer membrane that plays a role in spore formation. The spore coat is essential for protection 
against decontaminating agents and the environment. Finally, the exosporium layer that 
surrounds the spore is critical in pathogenesis as it helps in transportation of the spore from host 
to host [37].  
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a. 
 
 
b. 
 
Figure 3 - C. difficile sporulation pathway and spore model 
(a.) Suggested sporulation pathway as described by Paredes-Sabja et al. (2014), which utilises 
the well-known Bacillus subtilis sporulation pathway as a model. (b.) Layers of a C. difficile 
spore. [37] 
 18 
 
1.6 Antibiotic resistance 
Clindamycin-associated diarrhea was observed in 1974 and the link between pseudomembrane 
colitis and C. difficile was made in 1978, the prevalence of C. difficile infection has been on the 
rise since the early 2000s [3], [11], [13]. Furthermore, the majority of the observed cases of CDI 
are in health-care settings such as hospitals and long-term care facilities [6], [43]. One of the 
reasons for the rise in incidence of CDI is the increased use of antibiotics. The fluoroquinolone-
resistant hypervirulent strain NAP1/BI/027 came into prominence in the beginning of the 
millennium in Quebec, Canada when the use of fluoroquinolones was high in the medical 
community [44].  
 
Fluoroquinolones are broad-spectrum antibiotics that work by inhibiting bacterial type II 
topoisomerases that are involved in DNA replication. Because DNA is a large, coiled double 
helix structure, torsional stress called supercoiling occurs frequently. Also, supercoiling is used 
to compact DNA. Type II topoisomerases function by cutting both DNA strands and relieving 
the coiling stress, allowing for replication processes to continue. DNA gyrase subunit A is a type 
II topoisomerase (GyrA) and is the target of fluoroquinolones. Under normal circumstances, 
GyrA would bind to the DNA prior to cutting it to form an enzyme-DNA complex. When 
fluoroquinolones are present, however, they bind to the GyrA enzyme which will then bind to 
the DNA to form a fluoroquinolone-enzyme-DNA complex. The enzyme can then cut the DNA 
but the drug interaction disables the enzyme’s ability to re-ligate the DNA, which will lead to 
eventual cell death [45], [46].  
 
 19 
 
Whole-genome sequencing of a collection of C. difficile NAP1/BI/027 strains has revealed that 
resistance to fluoroquinolones was acquired by a single nucleotide mutation in the GyrA (gyrA) 
gene. This causes the threonine at position 82 to be changed to an isoleucine (Thr82Ile). This 
point mutation does not cause any functional loss in the protein but greatly reduces the binding 
efficiency of the drug [45], [46]. It was also found that this acquired resistance happened in two 
separate occasions, and gave rise to two separate lineages that have been named FQR1 and 
FQR2. These mutational events have happened in the very recent past, FQR1 lineage was 
thought to have been established in 1993 while the FQR2 lineage was established in 1994. It is 
thought that it was these mutations that gave rise to acquired resistance to fluoroquinolones 
which facilitated the outbreak of NAP1/BI/027 strains in the early 2000s [45]. Whole genome 
sequencing of C. difficile strain 630 (epidemic type X), revealed the resistance genes to 
tetracycline and erythromycin, daunorubicin, bacitracin, nogalmycin, and beta-lactams [47]. It 
has become evident that C. difficile can acquire resistance to antibiotics quite easily, which 
makes it very problematic to deal with. As mentioned earlier, metronidazole is the first-line of 
treatment for CDI, and certain strains such as ribotype 001 have started showing lowered 
susceptibility when tested in 2005 compared to strains of the same ribotype 10 years earlier [48]. 
This is making the infections harder to treat and is leading to a rise in infection recurrence. 
 
1.7 Epidemiology of C. difficile 
C. difficile is the cause of the most common nosocomial infection in the developed world, and 
the incidence of infection has steadily been on the rise [9], [20]. The University of Pittsburgh 
Medical Centre reported that the number of C. difficile infections between 2000 and 2001 had 
doubled from what had previously been reported between 1990 and 1999 [2]. It was during that 
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same time that the NAP1/BI/027 strain was first identified as the strain causing outbreaks in the 
province of Québec in Canada [43]. A study in that province showed an increase in infection 
rates from 35.63 cases per 100,000 population in 1991 to 156.3 cases per 100,000 population in 
2003 [18]. 
  
1.7.1 Symptomatic vs. asymptomatic 
Patients that are colonized with C. difficile can be divided into two groups: symptomatic and 
asymptomatic. In theory, a symptomatic patient is a patient who is colonized with C. difficile and 
is exhibiting symptoms of the illness, while an asymptomatic patient is a patient that is colonized 
with C. difficile but has no symptoms of the illness. However, this definition is not so obvious in 
a real life situation, considering that the illness is brought about from the treatment of another 
illness, in patients who often suffer from a plethora of other co-morbidities. The primary 
symptom of CDI is the onset of persistent diarrhea, which is defined as having 3 or more 
unformed stools (stools that take the form of the container) within 24 or less consecutive hours 
[21], [49]. Recently, physicians are aware of CDI occurring after beginning an antibiotic 
treatment, and will generally test stool for C. difficile upon the onset of diarrhea to confirm the 
presence of the organism. A symptomatic patient is then defined as a person who has developed 
diarrhea, and there is confirmation of C. difficile by a positive stool test for C. difficile toxins, the 
detection of toxigenic C. difficile, or finding evidence of pseudomembranous colitis by 
endoscopy [21]. It is however harder to define concretely what consists of an asymptomatic 
patient. There have been many attempts to define the asymptomatic patient.  In my thesis, we 
define a patient as asymptomatic if C. difficile is detected via either the Cepheid GeneXpert at 
HSN’s clinical laboratory or by culture, but the patient is not exhibiting any signs of diarrhea. 
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One must also take into account the patient’s normal bowel movements; if a patient normally has 
looser stools several times a day, it may not be considered to be diarrhea by the physician. This is 
often seen in cases where patients have loose stool due to other co-morbidities, or current 
medication for the treatment of these co-morbidities. 
 
1.7.2 Diagnosis 
When assessing a patient, at least one of the following criteria must be met to determine whether 
a patient has a CDI [6]: 
 The patient is diagnosed by a physician as having diarrhea (defined as 3 or more 
loose/unformed stools in 24 consecutive hours or less [49]) , fever, abdominal pain, ileus, 
or there is confirmation of positive C. difficile by enzyme immunoassay (EIA) or by 
polymerase chain reaction (PCR) tests 
 Pseudomembranes are observed by colonoscopy, sigmoidoscopy, histology or pathology  
 Toxic megacolon is diagnosed 
Furthermore, the CDI is considered to be a health-care associated CDI if: 
 The symptoms exhibited by the patients appear 72 hours after admission to the health-
care facility 
 If symptoms appear within four weeks of discharge from the health-care facility. 
These criteria do not apply to patients who are admitted as outpatients or at the emergency 
department.  
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1.7.3 Death linked to CDI 
Death is sometimes a consequence of the infection. However, not all deaths are attributed to a 
CDI; a physician must determine whether the death was brought upon by the CDI or if the 
infection played little to no role in the death of the patient. The Public Health Agency of Canada 
(PHAC) defined three levels of outcome [6]: 
 The death was directly linked to the CDI and the patient had no other condition that could 
have caused death 
 The death was indirectly linked to the CDI; the patient’s death was not primarily due to 
the infection, though it did play a role in the death 
 The death was unrelated to CDI. 
 
1.7.4 Rates of CDI 
Rates of colonization, infection, morbidity and mortality all vary greatly according to regions; in 
fact, incidences of infection vary greatly, including Canada. In a report looking at incidences and 
costs of CDI in Canada, Levy et al. reported that in 2012 there were 9,962 C. difficile infections 
in Ontario, while its neighbouring province of Québec had 16,562 confirmed cases [43]. For the 
purpose of this study, we will focus on CDI cases at Health Sciences North, in Sudbury, Ontario 
Canada.   
Since 2009, C. difficile infections are now “nationally notifiable diseases”, and must be reported 
to the provinces Ministry of Health (in Ontario, this is the Ministry of Health and Long Term 
Care [MOHLTC]).  CDIs are generally reported per 10,000 patient days:  
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝐷𝐼 𝑐𝑎𝑠𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑑𝑎𝑦𝑠
 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 × 10,000 
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where patient days is defined as the total number of days all patients have stayed at a health-care 
facility for the surveillance year [6]. Furthermore, the attributable mortality rate (deaths directly 
or indirectly caused by CDI) is defined as: 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑑𝑒𝑎𝑡ℎ𝑠 𝑑𝑖𝑟𝑒𝑐𝑡𝑙𝑦 𝑜𝑟 𝑖𝑛𝑑𝑖𝑟𝑒𝑐𝑡𝑙𝑦 𝑐𝑎𝑢𝑠𝑒𝑑 𝑏𝑦 𝐶𝐷𝐼
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐶𝐷𝐼 𝑐𝑎𝑠𝑒𝑠
 𝑝𝑒𝑟 𝑦𝑒𝑎𝑟 × 100 
 
The Public Health Agency of Canada (PHAC) released a surveillance report that spanned from 
January 1
st
, 2007 to December 31
st
, 2012. The data was collected from hospitals throughout 
Canada with the exception of the territories, which were not required to submit rates. The report 
showed that despite a small decrease in incidences in 2009, the number of health-care associated 
CDI (HA-CDI) cases have stabilized, despite increased efforts by health care facilities to avoid 
spread to decrease these numbers. Between 2007 and 2012, the average rate per 10,000 patient 
days was 6.48, with a low in 2009 with 5.81 per 10,000 patient days and a high in 2008 at 7.47 
per 10,000 patient days. The average patient age was 70 years old. From the 18,871 reported 
cases between 2007 and 2012, 454 people lost their lives, and 152 of those deaths were directly 
or indirectly linked to the CDI [6]. (Table 1) 
 
About 30% to 45% of all CDI cases are thought to be recurrent [43], [50], [51]. Recurrent C. 
difficile infections are cases in which the symptoms re-appear 28 ± 2 days after the end of the 
initial treatment for CDI. Recurrent cases can be divided into two categories: relapse in which 
the same strain is seen to infect the patient account for about 82% of recurrent cases, and 
reinfection from another strain accounts for 18% of recurrent cases [50]. 10,885 recurrent CDI 
cases were recorded in Canada in 2012 [43]. 
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Table 1 - Reported C. difficile cases in Canada between 2007 and 2012 
  2007 2008 2009 2010 2011 2012 
No. of HA-CDI cases 3,271 3,192 2,483 3,026 3,417 3,482 
No. of total patient days 4,832,597 4,274,020 4,270,868 4,945,856 5,141,450 5,766,774 
Rate per 10,000 patient days 6.77 7.47 5.81 6.12 6.65 6.04 
Average age 70.5 70.7 69.6 70.4 69.4 69.6 
No. of deaths (direct or indirect)  30 23 13 26 36 24 
 
The data was adapted from the surveillance report released by the Public Health Agency of Canada in 2012 entitled “Healthcare-
Associated Clostridium difficile Infections in Canadian Acute-Care Hospitals”. The number of hospital-associated CDI cases, number 
of patient days, rate per 10,000 patient days, average age, number of deaths (direct or indirect) and attributable mortality rate were 
drawn from the report and tabulated for clarity [6]. 
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MOHLTC has been keeping their records tabulated and accessible to the public since 2008 
(http://www.hqontario.ca/System-Performance/Hospital-Care-Sector-Performance). Between 
2009 and 2015, the Ontario average rate of HA-CDI was 3.05 per 10,000 patient days. The 
Ontario average rate of HA-CDI per 10,000 patient days between 2009 and 2012 has always 
been lower than the national average rate by about half (3.05, 3.06, 3.41 and 3.39 in Ontario vs. 
5.92, 6.21, 6.72 and 6.12 nationally for 2009, 2010, 2011 and 2012 respectively). Compared to 
the average from all the other hospitals in Ontario, Health Sciences North has been above the 
provincial average rates except in 2009 and in 2011. It must be noted that since the data includes 
all Ontario hospitals, there is a bias as the small community hospitals tend to have rates of 0.0 
per 10,000 patient days. This is due to the fact that any patient with complications is sent to the 
bigger acute hospitals for treatment. Hence, it is more accurate to compare the CDI rates of HSN 
to other acute teaching hospitals as they are classified. In the database provided by the 
MOHLTC, there are 27 of these hospitals in Ontario. While HSN is closer to those CDI rates, it 
still is above the acute teaching hospital HA-CDI rates other than 2009 and 2011. When looking 
at the CDI rates for the years that coincide with the years of samples collected for this project 
(2013-2015), the annual HA-CDI average rate at HSN was 4.92, 4.18 and 3.57 per 10,000 patient 
days while the acute teaching hospital averages were 3.00, 2.75 and 2.68 per 10,000 patient days 
for 2013, 2014 and 2015 respectively [52] (Table 2). 
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Table 2 - CDI rates per 10,000 patient days at Health Sciences North, compared to Ontario, Ontario acute teaching hospitals 
and Canada wide rates 
  2009 2010 2011 2012 2013 2014 2015 
Health Sciences North 1.43 4.73 1.90 4.38 4.92 4.18 3.57 
Ontario 3.05 3.06 3.41 3.39 3.00 2.75 2.68 
Ontario acute teaching hospitals 3.65 4.04 4.40 4.17 3.97 3.59 3.48 
Canada 5.92 6.21 6.72 6.12 
    
The rates of C. difficile infections per 10,000 patient days at Health Sciences North, when compared to the province of Ontario and 
Canada average CDI rates. Health Sciences North is considered an acute teaching hospital, according to the MOHLTC, and as such 
the rates for other acute teaching hospitals in the province of Ontario were included to provide a more realistic comparison. This is 
mostly due to smaller community hospitals having CDI rates of 0.0 per 10,000 days since any complicated patient case is sent to the 
nearest acute hospital for treatment. Adapted from the MOHLTC website http://www.hqontario.ca/System-Performance/Hospital-
Care-Sector-Performance (2016) [52]. 
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1.7.5 Cost of CDI 
While most studies focus on the cost of C. difficile infections on human lives, we must not forget 
that the infection also has a high socioeconomic cost. The Center for Disease Control (CDC) in 
the United States of America (USA) estimates the cost of CDI to be above US $3.2 billion per 
year [9], [43].  Here in Canada, the total cost of CDI is much lower than the reported cost of CDI 
in the USA, which is attributed to the fact that we represent only about 10% of the USA 
population. It is also worthwhile to remember that in the USA, the cost of hospitalization falls on 
the patient, but in Canada, the health-care bill is paid for by the publicly funded health-care 
system. Levy et al. set out to find an estimate of the cost of CDI to the Canadian health-care 
system. According to the data extrapolated by Levy et al., there were an estimated 37,932 
identified episodes of C. difficile infections in 2012. This number did not only include the HA-
CDI, but all reported infections which include community-acquired infections, outpatients, 
emergency department visits, long-term care facilities, and recurrence cases. A total of 20,002 of 
the 37,932 CDI cases were treated in hospital, 16,326 were treated in the community, and 1,604 
were treated in long-term care facilities. Furthermore, out of the 37,900 cases of CDI, 10,900 
cases were recurrent, and of the recurrent cases 7,980 (21%) were relapsed cases (Table 3). 
 
There were many factors to take into consideration when evaluating the cost of CDI. First, all 
CDI cases had to be divided by severity to determine the type of care that was provided to the 
patient. The classification used was that of the Society for Healthcare Epidemiology of America-
Infectious Diseases Society of America (SHEA-IDSA): mild-to-moderate, severe, and fulminant. 
Secondly, all attributable costs were taken into account, and this includes: laboratory tests, 
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hospitalizations (which include hospitalization that were not related to CDI, but extended due to 
CDI), medication, surgical procedures, and cost of physicians. 
 
After all these considerations, Levy et al., estimated that the cost to the Canadian health-care 
system was CAD $281 million. Approximately 90% (CAD $260 million) of the cost was due to 
the cost of hospitalization, CAD $12 million was the price paid to patients of the community, and 
another CAD $10 million was accrued in lost productivity from patients who could not work due 
to the infection. The Canadian health-care budget for 2012 was CAD $207 billion, meaning that 
the cost of treating CDI represents about 0.1% of the health-care budget. It should also be noted 
that as stated before, the Canadian population represents about 10% of the American population, 
the CAD $281 million spent on CDI in 2012 represents about 9% of the American reported US 
$3.2 billion [43]. Cost per capita for treatment of CDI in Canada is CAD 8.08$ (US 6.06$ at the 
time of redaction) per person while in the United States of America the cost per capita is US 
10.23$ per person.  
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Table 3 - Incidence, type, and severity of CDI in hospitals, communities, and long-term 
care facilities 
Location Characteristic of infection Incidence Percentage 
Hospital 
  
20,002 53 
 
Type of infection 
  
  
New infection 14,593 73 
  
First relapse 3,134 16 
  
Subsequent relapse 1,020 5 
  
Reinfection 1254 6 
     
 
Disease severity 
  
  
Mild-to-moderate 12,155 61 
  
Severe 7,435 37 
  
Fulminant 412 2 
     Community 
  
16,326 43 
 
Disease severity 
  
  
Mild-to-moderate 13,061 80 
  
Severe 3,265 20 
  
Fulminant 0 0 
     Long-term care facilities 
  
1,604.00 4.00 
 
Adapted from Levy et al. (2015) [43]  
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1.7.6 Risk factors 
There are several factors that increase the risk of developing C. difficile infection. First and 
foremost is exposure to antibiotics, especially fluoroquinolones [1]. As stated before, 
clindamycin was found to be a catalyst to developing CDI back in 1973 when it was the 
preferred antibiotic to treat intestinal tract infections [3], [10], [11]. With exposure to antibiotics 
on the rise, C. difficile is slowly developing resistance to some of the antibiotics used to treat it, 
such as metronidazole [3].  
 
Another risk factor is the patient’s age. Most recent reports are showing a trend where there is an 
increased incidence of CDI cases in patients above the age of 65; people over the age of 65 years 
old are 10 times more likely to acquire a C. difficile infection than people younger than 20 years 
old [1], [2], [18]. It is thought that the sharp increase in CDI cases after the age of 65 is due to 
immunosenescence: the progressive deterioration of the components of the innate and adaptive 
immune systems [1]. There have been many studies that show that an effective humoral response 
to TcdA and TcdB can help prevent a C. difficile infection or decrease its effects leading to the 
immunosenescence theory [1], [53], [54]. 
 
Finally, another important risk factor is the environment; in particular health-care facilities. 
Health-care facilities provide an area of high-risk cross-contamination, especially between 
health-care providers and patients. Furthermore, susceptible patients may come in contact with 
objects that previously infected patients may have also been in contact with, namely toilets, 
hand-rails and bed-rails [1], [55]–[57]. This risk has been of high concern since the early 2000s, 
and cleaning reforms and more intensive isolation measures throughout health-care facilities 
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have been put in place to avoid cross-contamination [58], [59]. However, increased lengths of 
stay in health-care facilities is still a great risk factor to susceptible patients [18].  
 
1.8 Clinical diagnosis and treatment 
The first indication of a C. difficile infection is the presence of diarrhea. Physicians pay close 
attention to patients over the age of 65 in health-care facilities who are given a course of 
antibiotics. Guidelines have been set by the Infectious Disease Society of America (IDSA) and 
the Society for Healthcare Epidemiology of America (SHEA) with strong recommendations for a 
best course of action when dealing with a possible CDI [1], [9], [20], [49]. Should a physician 
suspect that there might be a CDI case (i.e. the presence of diarrhea), a stool sample is collected 
from the patient where one of several clinical tests can be performed. In previous years, enzyme 
immunoassay (EIA) was the test of choice for the detection of toxin in feces; however, with 
greater range in test sensitivity (31-99%) and the drop in cost of nucleic acid amplification tests 
(NAATs), NAATS such as PCR became the new standard of testing [1], [9]. Due to the higher 
sensitivity of tests such as PCR, the incidences of CDI may rise due to a potential over 
diagnosing [60]. However, the potential of over diagnosing is still lower than the false-positive 
results given by EIA testing [61]. 
 
At HSN, the real time-PCR Cepheid GeneXpert has replaced the EIA that was previously being 
used [61].  The GeneXpert platform is fitted for the company’s “all-in-one” cartridges, which 
contain all the reagents and quality controls needed for the test. The entire test can be completed 
in less than 1 hour, including the forty-five minute runtime of the instrument, using the patient’s 
stool sample. The cartridges contain 3 sets of primers to help in the detection of toxigenic C. 
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difficile: a set of primer for the tcdB gene, a set of primers for the tcdC gene that contains a 
deletion at nucleotide 117, and a set of primers for the cdt binary toxin gene. Specifically, should 
the strain be positive for all three of those genes, it is said to be presumptive for the hypervirulent 
strain NAP1/BI/027, which is critical knowledge for the health-care facility’s infection control 
department in dealing with appropriate measures of isolation and treatment [62], [63]. 
 
In the event that a patient’s test is positive for C. difficile, the physicians must assess their 
patients to initiate the best course of treatment. The physicians must first determine the severity 
of the patient’s signs and symptoms which will determine what treatment will be given. 
IDSA/SHEA both have a three point classification system for the severity of the symptoms of a 
C. difficile infection with a recommended course of treatment for each severity level [9], [20], 
[49].  
1. Mild-to-moderate – Patients with mild-to-moderate CDI basically only have diarrhea as a 
symptom. Some patients may complain of mild abdominal tenderness and discomfort due 
to the high frequency of bowel movements, which exceed 3 per 24 consecutive hours. 
Treatment for mild-to-moderate CDI is a course of metronidazole, 500mg ingested orally 
three times daily for 10 days. Should the patient be unable to take metronidazole, or if 
there is no improvement in the patient’s health after 5 to 7 days, 125mg of vancomycin 
may be taken orally 4 times daily for 10 days.  
2. Severe – In severe cases, patients will have considerable diarrhea and serum albumin 
levels smaller than 3g/dl. They will often have an elevated white blood cell count of over 
15,000 cells/mm
3
 and abdominal tenderness. Treatment for severe disease is a course of 
vancomycin, 125mg ingested orally 4 times daily for 10 days. 
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3. Severe and complicated – In a severe and complicated C. difficile infection, patients are 
usually admitted to the intensive care unit due to the severity of the illness. Their 
symptoms also include fever above 38.5
o
C, hypotension, significant abdominal distention 
or ileus, a white blood cell count greater than 35,000 cells/mm
3
 or lower than 2,000 
cells/mm
3
, and serum lactate levels lower than 2.2 mmol/L. Antibiotic treatment at this 
point is very aggressive, with a recommended 500mg of vancomycin taken orally 4 times 
daily, 500mg IV of metronidazole every 8 hours, and 500mg in 500mL saline 
administered rectally (as an enema) 4 times daily. Should antibiotic treatment fail, other 
more drastic alternative treatments may be used, such as fecal transplant therapy and 
surgery to remove the affected colon depending on the severity of the case. 
Furthermore, patient who present with recurrent cases of CDI are often moved from 
metronidazole treatment to a vancomycin treatment. After more than 3 recurrences, alternative 
therapies such as fecal transplant are also explored [9].  
 
1.9 Project rationale 
While C. difficile research is more common in bigger centres in Canada and around the world, 
the impact and genetic diversity of C. difficile in Northern Ontario is relatively unknown. 
Northern Ontario is a vast area, and is home to many secluded communities. Health Sciences 
North provides a health-care hub for all these communities, and patients often travel large 
distances to get specialized care in Sudbury.  
 
Stool samples that were used in this project were procured from two sources. The first source of 
samples was from patients admitted to the two wards with the most reported cases of CDI: the 
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respiratory unit and the oncology and palliative care unit. These patients were asked to 
participate in our study, and gave consent for us to collect their stool during the first 48 hours of 
their stay at HSN. This was done according to the HSN’s Research Ethics Board (REB) 
guidelines. The second source of samples was from HSN’s clinical lab. As per HSN REB, 
medical waste samples may be used for research purposes. These stool samples were left over 
samples from patient who had get tested for CDI during their stay at HSN. These samples come 
from all wards at HSN. 
 
We have established a library of C. difficile samples from patients admitted to HSN in order to 
examine the genetic diversity of C. difficile in Northern Ontario.  These samples were then used 
to assess whether there is a link strain diversity (phenotypic variance) and virulence. 
Furthermore, using the patients’ medical and treatment histories, we then evaluated whether 
specific bacterial genotypes or phenotypes accurately predicted prognosis and/or treatment 
outcome.   
 
Bacterial genotypes and phenotypes that were evaluated were antibiotic susceptibility, toxin 
production, and microbial spore load. We chose these three factors as antibiotics lead to the onset 
of the infection, toxins cause the symptoms, and spores propagate the organism to its next host.   
 
1.10 Research objectives 
1. To build a well annotated cryorepository of C. difficile samples from patients at HSN 
treated for a CDI. 
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• Isolate, identify and store clinical strains 
• Develop a database to record strain genotypes and phenotypes 
2. To perform assays on the collected C. difficile strains including: 
• Ribotype 
• Toxin production 
• Microbial spore load 
• Antibiotic susceptibility 
3. Investigate the correlation between phenotypes and genotypes of C. difficile and clinical 
outcome from CDI at HSN. 
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2.0 Media and Reagents 
The recipes for all media and reagents used in this study are described below: 
2.1 Columbia broth (CB) 
35g of CB base (BD, Sparks, MD, USA, Cat: 294420) in 1000mL ddH2O brought to a boil. 
Media sterilized by autoclaving, stored at room temperature in a 1L Corning bottle. 
 
2.2 Brain heart infusion broth (BHI) 
37g of BHI base (Oxoid, Basingstoke, Hampshire, England, Cat: CM1135) in 1000mL ddH2O 
brought to a boil. Media sterilized by autoclaving, stored at room temperature in a 1L Corning 
bottle. 
 
2.3 Brucella supplemented broth (BSB) 
28g of Brucella agar base (BD, Sparks, MD, USA, Cat: 294420) in 1000mL ddH2O brought to a 
boil. Media sterilized by autoclaving. 10mL vitamin K/hemin solution (QueLab, Montreal, QC, 
Canada, Cat: 8751) was filtered into the broth with a 2micron syringe filter. The medium was 
stored at room temperature in a 1L Corning bottle. 
 
2.4 Brain heart infusion yeast extract taurocholate agar (BHI-YT) 
37g BHI base (Oxoid, Basingstoke, Hampshire, England, Cat: CM1135), 5g yeast extract (BD, 
Sparks, MD, USA, Cat: 212750), 1g L-cysteine hydrochloride monohydrate (Sigma-Aldrich, St. 
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Louis, MO, USA, Cat: C7880), 1g taurocholate (Sigma-Aldrich, St. Louis, MO, USA, Cat: 
T4009), 15g bacteriological agar (QueLab, Montreal, QC, Canada, Cat: QB-39-0221) were 
dissolved in 1000mL ddH2O and brought to a boil. The medium was sterilized by autoclaving 
and distributed (20mL) into 100mm petri dishes.  
 
2.5 Clostridium difficile selective agar (CDSA) 
69g of C. difficile agar base (Oxoid, Bakingstoke, Hampshire, England, Cat: CM0601), 1g 
taurocholate (Sigma-Aldrich, St. Louis, MO, USA, Cat: T4009) was dissolved in 920mL of 
ddH2O, brought to a boil and sterilized by autoclaving, and then cooled to 60
o
C. Medium was 
supplemented with 2.5mL of 2.4mg/mL Norfloxacin, 2.5mL of 12.8mg/mL Moxalactam, and 
70mL defibrinated horse blood (Nutri-Bact, Terrebonne, QC, Canada, Cat:4281). The medium 
was distributed (20mL) into 100mm petri dishes and stored at 4ºC until use.  
 
2.6 Norfloxacin stock 
In a 50mL centrifuge tube, 240mg of Norfloxacin (Sigma-Aldrich, St. Louis, MO, USA, Cat: 
N9890) and 0.2mL of concentrated hydrochloric acid, 36%-38% (Sigma-Aldrich, St. Louis, MO, 
USA, Cat: H1758) were added to 50mL ddH2O. The content of the tube was mixed gently until 
dissolved. Solution was dispensed into a 100mL volumetric flask and topped up to 100mL with 
ddH2O. Solution was syringe filtered (0.2micron) into 15mL centrifuge tubes (10mL/tube), and 
placed in -80
o
C freezer for storage. 
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2.7 Moxalactam stock 
In a 50mL centrifuge tube, 1280mg of Moxalactam (Sigma-Aldrich, St. Louis, MO, USA, Cat: 
M8158) and 10g of L-cysteine Hydrochloride monohydrate (Sigma-Aldrich, St. Louis, MO, 
USA, Cat: C7880) were added and topped up to 50mL with ddH2O. Centrifuge tube was gently 
mixed until dissolved. Solution was dispensed into a 100mL volumetric flask and topped up to 
100mL with ddH2O. Solution was syringe filtered (0.2micron) into 15mL centrifuge tubes 
(10mL/tube), and placed in -80
o
C freezer for storage. 
 
2.8 Brucella blood agar (BBA) 
43g of Brucella agar base (QueLab, Montreal, QC, Canada, QB-39-0606) and 15g of bacterial 
agar (QueLab, Montreal, QC, Canada, Cat: QB-39-0221) were added to 1000mL ddH2O and 
brought to a boil. The medium was sterilized in the autoclave for 20 minutes on liquid cycle, 
120kPa, 121ºC. The medium was cooled to 60ºC in a water bath, and supplemented with 50mL 
laked sheep blood (Nutri-Bact, Terrebonne, QC, Canada, Cat: 4147) and 5mL vitamin K/hemin 
solution (QueLab, Montreal, QC, Canada, Cat: 8751). The medium was dispensed in either 
150mm petri dishes (70mL) or 100mm petri dishes (20mL). 
 
2.9 Sodium hydroxide stock (1N) 
40g of of NaOH (Sigma-Aldrich, St. Louis, MO, USA, Cat: S5881) was dissolved in 1L of 
ddH2O.  
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2.10 Ethylenediaminetetraacetic acid (EDTA) 
3.72g of EDTA (Sigma-Aldrich, St. Louis, MO, Cat: E5134) was added to 200mL ddH2O (0.5 
M) and dissolved by adjusting the pH to 8.0 with 1N NaOH. 
 
2.11 10X tris/borate/EDTA (TBE) buffer 
In 400mL of ddH2O, 53g of trizma base (Sigma-Aldrich, St. Louis, MO, USA, Cat: T1503) and 
27.5g of boric acid (Sigma-Aldrich, St. Louis, MO, USA, Cat: B7901) were dissolved along with 
20mL of 0.5M EDTA. pH was adjusted to 8.0 with 1N NaOH. The volume was topped up to 
500mL with ddH2O. 
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3.0 Methods 
3.1 Sample processing 
Stool samples for the project were received from 2 different sources at HSN between December 
3
rd
, 2013 and June 17
th
, 2015; either by consenting patients to participate in our study (patient 
recruitment) or from medical waste from a physician ordered C. difficile test (clinical samples). 
All stool samples were tested for C. difficile using two methods: by the Cepheid GeneXpert, and 
by bacterial culture of stool samples on selective media.  
 
3.1.1 Patient recruitment 
Patients that were admitted to the Oncology Ward (Med4 North) and the Respiratory Ward 
(Med6 South) were visited by one of our clinical research co-ordinators (Barbara Rickaby, 
Pamela Leduc, Carolyn Truskoski) and asked to participate in our study in the 24 hours 
following their admission to the ward. The two wards in which patients were consented were 
chosen based on their reported rates of CDI, as well as the frequency of outbreaks. The 
consenting of patients was approved by HSN’s Research Ethics Board (REB). Should the patient 
consent to participate in our study, they were asked to donate a stool sample that was to be 
collected by the nursing staff within 72 hours of admission in a specimen cup. The sample was 
then sent to HSN’s clinical laboratory where it was processed for storage and tested on the 
Cepheid’s GeneXpert platform. The samples received from consented patients were given the 
designation “CDST”, followed by the next available number in the database (i.e. CDST0001, 
CDST0002). 
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3.1.2 Clinical samples 
Clinical stool samples were given to us after use at HSN’s clinical laboratory as medical waste. 
Patients in this case did not need to be consented as medical waste may be used for research 
purposes. These stool samples were from patients admitted to any ward at HSN that exhibited 
CDI symptoms from which a physician ordered a test to confirm CDI. The samples were 
collected in a specimen cup by the nursing staff, and sent to HSN’s clinical laboratory. Stool 
samples were kept in a refrigerator at 4
oC until testing by Cepheid’s GeneXpert was complete, at 
which time they were processed for storage. Only stool samples that were positive for C. difficile 
were processed and picked up from the clinical laboratory. Upon receiving the samples, they 
were numbered arbitrarily using a letter and number system; samples from the clinical lab were 
given a designation of “CD” followed by the next number available in the database (i.e. CD0001, 
CD0002, etc.). This was done in accordance with the research ethics board (REB) guidelines, 
which states that the samples must be given a number that is untraceable to the patient.  
 
3.1.3 Patient profiles 
All patient information needed for the research was gathered from Meditech, the medical 
database that is used at HSN. This was done in accordance with the REB guidelines. This 
information includes: hospital ward the patient was admitted to, year of birth and age, sex, 
primary diagnosis, and date of admission and date of discharge or death. As per REB, any 
documents linking data back to the patient were kept in a locked room or encrypted to prevent 
unintended disclosures.  
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3.1.4 Cepheid’s GeneXpert diagnostic platform 
Cepheid’s GeneXpert is real-time PCR instrument that HSN’s clinical lab utilises to confirm 
CDI cases.  The test was carried out according to manufacturer’s protocol. Each kit contains a 
sterile swab, transfer pipette, sample reagent, and Xpert C. difficile cartridge. The sterile swab 
was immersed in the stool sample as to get uniform stool coverage around the swab. The swab 
was then dipped in the sample reagent bottle, and the stem of the swab was snapped off along the 
dotted line. The sample reagent and swab were vortexed for 10 seconds at high speed. Using the 
transfer pipette, the entirety of the sample reagent bottle was transferred to the “S” chamber of 
the Xpert C. difficile cartridge. At this point, the cartridge was loaded in the Cepheid GeneXpert 
instrument and the test was launched.  The test detects the presence of the tcdB gene, as well as 
the binary toxin cdt and the tcdC in the pathogenicity locus with a deletion at nucleotide 117. 
Included in the cartridge are two quality controls: a Sample Processing Control (SPC) and a 
Probe Check Control (PCC). Bacillus globigii spores are used as SPC to ensure that the stool 
samples were processed correctly while the PCC ensures proper functioning of the cartridge 
itself.  
 
3.1.5 Sample preparation and storage 
One gram of each stool sample provided was placed in a 15mL conical tube. 4mL of 10% 
glycerol was then added to the conical tube, and the sample was homogenized by vortexing 
thoroughly. Samples were brought back to the Health Sciences North Research Institute 
(HSNRI) laboratory where they were aliquoted into 2mL cryovial tubes. The cryovial tubes were 
stored in a -80
o
C freezer until further processing was to take place.  
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3.1.6 Isolation of C. difficile  
C. difficile was isolated from the stool samples that were prepared for storage in HSN’s clinical 
laboratory and frozen at -80
o
C. Once thawed, ethanol shock was performed by taking 0.1mL of 
stool sample and aliquoting it to cryovials containing 0.1mL of 100% ethanol (anhydrous) 
(Commercial Alcohols, Brampton, ON, Canada, Cat: P016EAAN).  Samples were left to 
incubate at room temperature for 1 hour. After the ethanol shock was completed, 0.1mL of 
shocked sample was transferred to a reduced CDSA plate and spread using a T-shaped sterile 
spreader. Plates were incubated under anaerobic conditions in a Plas-Lab controlled atmosphere 
chamber containing a gas mixture of 15% CO2, 75% N2, <1% H2 at 37
o
C for a period of 5 to 7 
days. Incubation time was dictated by how well the organism had grown after the 5
th
 day. Were 
the colonies still too small (smaller than 2mm in diameter), they were allowed to incubate for 2 
days more. 
 
After the initial incubation period, the CDSA plates were removed from the anaerobic chamber, 
and a single colony from each plate was lifted using disposable 1μL inoculating loops and 
transferred to a 15mL conical tube containing 5mL of pre-reduced BHI broth. The lids of the 
conical tubes were loosely capped, and the tubes were placed back under anaerobic conditions at 
37
o
C for a 5 day incubation period. 
 
Upon completion of the 5 days incubation period, purity of culture was confirmed by 
morphological characteristics of colonies (beige to pink colonies, between 2 and 15 mm in 
diameter depending on incubation period, circular with lobate margins, and a flat and umbonate 
elevation), and by microscopy. Should the culture be found to be impure, a 1μL sterile 
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disposable inoculating loop was used to streak a sample of culture on a CDSA plate, which was 
incubated under anaerobic conditions at 37
o
C for an extra 5 days. This cycle was repeated until 
the culture was found to be pure. The pure culture was used for C. difficile spore production for 
storage as well as DNA extraction.  
 
3.1.7 C. difficile spore storage 
From the pure C. difficile isolates cultivated in BHI, a 1μL inoculating loop was charged and 
streaked liberally over a BHI-YT plate. BHI-YT plates were placed under anaerobic conditions 
at 37
o
C for a 7 day incubation period. Resulting colonies were scraped off the plates by pipetting 
2mL of sterile ddH2O directly onto the plate and using a T-shaped spreader to dislodge the 
colonies. Resulting mixture was transferred to a 2mL cryovial and vortexed thoroughly to 
homogenize the colonies. Cryovials containing spores are kept in a cryovial box at 4
o
C 
indefinitely. To recover the spores, a 1µL inoculating loop can be charged with spores and 
streaked on a CDSA plate and incubated under anaerobic conditions for 5-7 days at 37
o
C.  
 
3.1.8 DNA extraction 
1.5mL of pure C. difficile isolates cultivated in BHI was transferred to a 2mL cryovial. Cryovials 
were centrifuged at 13,200 RPM for 3 minutes. Supernatant was discarded. Pallet was washed 
with sterile ddH2O and vortexed thoroughly. The isolates were centrifuged again (13,200 RPM, 3 
minutes) and the supernatant was discarded. Wash and centrifugation were repeated, and 
supernatant was discarded. 0.5mL of sterile 5% Chelex (Bio-Rad, Hercules, CA, USA, Cat: 
1422822) was added to each pallet. Isolates were placed on a hot block at 105
o
C for 20 minutes, 
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and then cooled in the refrigerator at 4
o
C. Isolates were centrifuged once more (13 200RPM, 3 
minutes) and the supernatant was transferred to a new cryovial. Supernatant was then frozen at -
20
o
C. 
 
3.2 Characterizations of C. difficile strains 
3.2.1 Toxinotyping  
The genetic method for toxinotyping was adapted from a multiplex PCR protocol described by 
Lemee et al. (2004) using three pairs of primers: two primers for triose phosphate isomerase (tpi-
F [5’-AAAGAAGCTAAGGGTACAA-3’] and tpi-R [5’-CATAATATTGGGTCTATTCCTAC-
3’]) (Sigma-Aldrich, St. Louis, MO, USA, Cat: 99343-003 & 99343-004) which generate a 
230bp amplicon and is a housekeeping gene that is conserved in all C. difficile strains with a 
unique sequence to the organism. This is used as a control which determines whether the 
organism is in fact C. difficile. Two primers for tcdA are used (tcdA-F [5’-
AGATTCCTATATTTACATGACAATAT-3’] and tcdA-R [5’-
GTATCAGGCATAAAGTAATATACTTT-3’]) (Sigma-Aldrich, St. Louis, MO, USA, Cat: 
99343-007 & 99343-008), which generates a 369bp amplicon, or an 110bp amplicon in strains 
that have a truncation in the tcdA gene. Another pair of primers specific for tcdB (tcdB-F [5’-
GGAAAAGAGAATGGTTTTATTAA-3’] and tcdB-R [5’-
ATCTTTAGTTATAACTTTGACATCTTT-3’]) (Sigma-Aldrich, St. Louis, MO, USA, Cat: 
99343-005 & 99343-006) generates a 160bp amplicon. Primers were prepared by first making a 
20X stock solution (5μL primers in 95μL RNAse and DNase free ddH2O) for each primer. Two 
working stock solutions of primers where then prepared with the following ratios: primer 
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solution 1 contained 17.9% tpi-F, 15.4% tpi-R, 35.9% tcdB-F and 30.8% tcdB-R while primer 
solution 2 contained 50.7% tcdA-F and 49.3% tcdA-R. 
 
Qiagen Multiplex PCR Plus kits (Qiagen, Hilden, Germany, Cat: 206152) were used for PCR, 
with a MasterMix solution made from the kit reagents in the following ratios: 100μL of 
MasterMix, 20μL of coral dye, 20μL of RNAse free H2O, 40μL of Q-solution, 10μL of primer 
solution 1 and 10μL  of primer solution 2. 
 
PCR 96-well plate or 8-well strips were loaded with 19μL of MasterMix solution and 1μL of C. 
difficile DNA. DNase/RNAse free ddH2O was used as blank control, ATCC strain 700057 was 
used as the tpi+/tcdA-/tcdB- control, ATCC strain 43594 was used as the tpi+/tcdA+/tcdB+ 
control, and ATCC strain 43598 was used as the tpi+/ΔtcdA/tcdB+ control. Amplification was 
performed on an Eppendorf MasterCycler Pro 6325 using the following cycles: an initial 5 
minutes at 95
o
C, followed by 30 cycles of: 30 seconds of DNA denaturation at 95
o
C, 90 seconds 
of primer annealing at 57
o
C, and 30 seconds of primer extension at 72
o
C, and a final step of 10 
minutes at 68
o
C. 
 
PCR amplicons were resolved for 1 hour on a 1% agarose gels (Sigma-Aldrich, St. Louis, MO, 
USA, Cat: A6877) in a ½ TBE buffer at 100 volts. The gel was stained with 1μg/mL ethidium 
bromide (Sigma-Aldrich, St. Louis, MO, USA, Cat: E8751) for 15 minutes, and photographed on 
a UV transilluminator using ProteinSimple FluorChem software. 
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3.2.2 Ribotyping 
PCR-ribotyping was adapted from a method by Bidet & Petit (1999), which itself was adapted 
from a method by Gürtler ( 1993), and then O’Neill (1996). The intergenic region in rRNA 
operons of C. difficile were PCR amplified using C. difficile genomic DNA and C. difficile 
specific 16S primer [5’-GTGCGGCTGGATCACCTCCT-3’] and 23S primer [5’-
CCCTGCACCCTTAATAACTTGACC-3’] (Sigma-Aldrich, St. Louis, MO, USA, Cat: 99343-
001 & 99343-002). A 20X primer solution was made by adding 5µL of primer to 95µL of 
DNase/RNAse free ddH2O. A Qiagen Multiplex PCR Plus kit (Qiagen, Hilden, Germany, Cat: 
206152) was used for PCR, and a MasterMix solution was prepared using the following reagents 
in these ratios: 100μL of MasterMix, 20μL of coral dye, 20μL of RNAse free H2O, 40μL of Q-
solution, 10μL of 16S primer solution and 10μL of 23S primer solution. 
 
Nineteen µL of the MasterMix solution was added to a 96-well PCR plate or 8-well PCR strip as 
needed, along with 1µL of C. difficile DNA. Plate/strips were placed on an Eppendorf 
MasterCycler Pro 6325 for the following cycles: an initial 5 minutes at 94
o
C, followed by 30 
cycles of: 60 seconds of DNA denaturation at 95
o
C, 60 seconds of primer annealing at 57
o
C, and 
60 seconds of primer extension at 72
o
C, and a final 10 minutes at 68
o
C after the 30 cycles. 
 
PCR amplicons were resolved by capillary electrophoresis using a DNA-1000 chip for the 
Agilent Bioanalyzer (Agilent, Waldbronn, Germany, Cat: 5067-1514). The manufacturer’s 
protocol was followed for preparation of the DNA-1000 chip. The chip was placed on the chip 
priming station, and 9µL of gel-dye matrix was pipetted to the well labelled G and primed for 1 
minute with 1mL of air through a syringe. The syringe was then released, and 9µL of gel-dye 
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was added to the other G well. 5µL of marker was added to wells 1-12, and the ladder well. 1µL 
of DNA ladder was added to the ladder well, and 1µL of each set of PCR amplicons was pipetted 
to wells 1-12. The chip was vortexed on the chip vortexer at 2400 RPM for 1 minute. The chip 
was then placed on the Agilent Bioanalyzer and allowed to run.  
 
Fingerprints generated by the Agilent Bioanalyzer were analyzed by the GelCompar II software 
(Applied Maths, Austin, Texas, USA) and matched up to our ribotype database. 
 
3.3 Biology of C. difficile strains  
3.3.1 Microbial spore load 
The amount of spores per gram of stool was determined for each of the patient stool samples. 
This was accomplished by first doing an ethanol shock as described in the C. difficile isolation 
protocol. After the 1 hour shock was complete, a dilution series was prepared for each shocked 
sample with pre-sterilized ddH2O to create 1/2, 1/10, 1/100, 1/1000, 1/10000, and 1/100000 
dilutions. 0.1mL of each dilution was spread on CDSA plates using a T-shaped spreader and 
incubated under anaerobic conditions for 48 hours. Colonies were counted after the incubation 
period to then determine the total spore load for the undiluted sample.  
 
To normalize the data against dry weight of stool samples, the moisture content of each stool was 
determined in order to have a true representation. 0.5mL of each stool sample was pipetted to 
cryovials and 0.05mL of 10% bleach was added to each sample and allowed to incubate at room 
temperature for 1 hour in order to sterilize the stool of microorganisms. The content of the 
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cryovials was transferred to pre-weighed aluminum tins, and the stool samples were weighed. 
Stool samples were placed in a drying oven for 1 hour at 120
o
C until the water had completely 
evaporated from the control tin. Tin and stool were weighed once more, and the moisture content 
was calculated as percentage water content. 
 
3.3.2 In vitro toxin production 
In vitro toxin production of each C. difficile isolate was determined using the C. difficile Tox 
A/B II EIA kit from TechLabs (Blacksburg, VA, USA, Cat: T5015). Spores from each sample 
were recovered on CDSA, and a single colony from each plate was inoculated in 5mL pre-
reduced BHI broth in a 15mL conical tube. Tubes were placed under anaerobic conditions at 
37
o
C until culture reached stationary phase (about 48 hours). Each culture was standardized to 
0.5 MacFarland standard equivalent by slowly pipetting culture into 5mL of pre-reduced BHI in 
calibrated glass tubes for the Fisher Scientific Cell Density Meter (model 40). Standardized 
cultures were placed under anaerobic conditions for 48 ± 2hours. Cultures were transferred to 
15mL conical tubes and centrifuged at 4500 RPM for 20 minutes at 4
o
C. Supernatant was 
transferred to another 15mL conical tube and stored at 4
o
C. 
 
Relative toxin levels in each supernatant were measured using the C. difficile Tox A/B II EIA kit 
from TechLab, according to manufacturer’s specifications.  Provided with the kit is a diluent, a 
conjugate, a substrate, a positive control, wash buffer, stop solution and microassay plate. The 
samples were prepared for the test by adding 50µL of culture supernatant to 200µL of diluent in 
1.5mL Eppendorf tubes. A series of 6 ten-fold serial dilutions were prepared from this. Then, 
50µL of conjugate was added to each needed well with 100µL of prepared diluted samples. 50µL 
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of the provided positive control was added to one well, and 50µL of diluent as negative control. 
ATCC 700057 strain was also used as a negative control (non-toxigenic C. difficile strain), and 
ATCC 43594 strain as positive control (toxigenic C. difficile strain). An adhesive wrap was 
placed over the used wells, and the plate was placed at 37
o
C ± 2
o
C for 50 minutes. Content of the 
wells was discarded, and wells were washed with wash buffer 5 times, tapping the inverted 
plates on paper towels after each wash. 100µL of substrate was added to each well and left to 
incubate at room temperature for 10 minutes, tapping the plate gently at the start and at 5 minute 
mark to allow the substrate to mix. 50µL of stop solution was added to each well at the end of 
the incubation period, and the plate was read on the BioTek Synergy H4 hybrid plate reader at 
450/620nm dual wavelength. For the test to pass quality control, the positive control must be 
≥0.500, and the negative control <0.080.  The test limit for a sample is 0.080, and any sample 
with a reading lower than this value was considered negligible. Toxin concentrations detectable 
by the kit are 0.8ng/mL for toxin A, and 2.5ng/mL for toxin B. Upon completion of the test, 
toxin values were determined, noting the dilution factor for each sample.  
 
3.3.3 Antibiotic susceptibility 
Antibiotic susceptibility and the minimal antibiotic inhibitory (MIC) concentration for various C. 
difficile strains was determined using BioMérieux E-Test strips and Oxoid M.I.C.Evaluator 
strips. Eight different antibiotics were used, based on their frequency of use at HSN’s Med4 
North and Med6 South clinics. The following antibiotic strips were used: vancomycin 
(Biomérieux, Marcy-l’Étoile, France, Cat: 412488), metronidazol (Oxoid, Bakingstoke, 
Hampshire, England, Cat: MA0103F), clindamycin (Oxoid, Bakingstoke, Hampshire, England, 
Cat: MA0119F), ciprofloxacin (Biomérieux, Marcy-l’Étoile, France, Cat: 412311), amoxicillin 
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(Biomérieux, Marcy-l’Étoile, France, Cat: 412243), benzyl penicillin (Biomérieux, Marcy-
l’Étoile, France, Cat: 412465), cefotaxime (Oxoid, Bakingstoke, Hampshire, England, Cat: 
MA0112F) and imipenem (Oxoid, Bakingstoke, Hampshire, England, Cat: MA0115F). 
 
Spores were recovered on CDSA plates from the spore stock and placed under anaerobic 
conditions at 37
o
C for 5 to 7 days incubation period. Once grown, a single colony from each 
plate was picked by a 1µL inoculating loop and placed in 5 mL of pre-reduced BSB broth for 48 
hour growth under anaerobic conditions at 37
o
C. After the incubation period, the cultures were 
used to inoculate 5mL of pre-reduced BSB broth in calibrated glass vials for the Fisher Scientific 
Cell Density Meter model 40 to standardize the culture to 0.5 MacFarland (OD 0.1 at 600nm). 
Using a floqswab, a lawn was created on 150mm or 100mm petri dish with BBA agar. On the 
150mm plates, 4 E-Test strips were placed at 12, 3, 6 and 9 o’clock positions, while on the 
100mm plate, only 1 E-test strip was used. Plates were placed under anaerobic conditions for 48 
hours ± 2hours, at which time the plates were taken out, and the MIC observed and recorded. To 
determine the MIC, the value at which the zone of inhibition ends on the E-Test strip was 
recorded.  
 
The analysis of the MIC values for the C. difficile strains was done by looking at the population’s 
distribution of the MIC values. The population distribution graphs were populated by entering 
the percentage of samples that were observed at specific MIC values in Microsoft Excel. The 
population distribution of the MIC values was compared to European Society of Clinical 
Microbiology and Infectious Diseases (EUCAST). Unfortunately, EUCAST does not have all the 
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clinical breakpoints of all the antibiotics that were used in this project, so we could not determine 
the resistance of the strains to certain antibiotics, but trends can be observed in those cases.  
 
3.4 Epidemiology 
3.4.1 Classification of patients’ symptom severity 
Using the guidelines set by the Infectious Disease Society of America (IDSA) and the Society 
for Healthcare Epidemiology of America (SHEA), the symptoms of the patients were reviewed 
and given a score between 0 to 3 based on reports by the physicians and clinical lab reports, all 
available on Meditech. 
1) Asymptomatic (score of zero) 
a) no symptoms (formed stool) 
2) Mild-to-moderate (score of 1) 
a) diarrhea (unformed stool, in excess of 3 per 24 consecutive hours) 
b) mild abdominal tenderness  
3) Severe (score of 2) 
a) considerable diarrhea  
b) serum albumin levels smaller than 3g/dl  
c) elevated white blood cell count of over 15,000 cells/mm3  
d) abdominal tenderness 
4) Severe and complicated (score of 3) 
a) considerable diarrhea 
b) fever above 38.5oC 
c) hypotension 
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d) significant abdominal distention or ileus 
e) white blood cell count greater than 35,000 cells/mm3 or lower than 2,000 cells/mm3 
f) serum lactate levels lower than 2.2mmol/L 
 
3.5 Statistical analysis 
All statistical analyses (box plots, Welch’s t-test, one-way ANOVA) were performed on Prism 
GraphPad version 5. 
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4.0 Results 
A flowchart representing all the steps from sampling to testing is found in appendix 1, and a 
tabulated database of all results is found in appendix 2. 
 
4.1 Sample processing and patient demographics 
4.1.1 Cohort 
A total of 57 C. difficile stool samples identified as positive by GeneXpert or by culture in the 
lab were gathered for the study. The samples were divided into two groups: asymptomatic and 
symptomatic. 23 of the samples were asymptomatic, 13 of them being males (ages 37-90, mean 
73) and 10 females (ages 21-76, mean 60.5), while 34 of the samples were symptomatic, 18 of 
them being males (ages 55-86, mean 70) and 16 females (ages 44-98, mean 76). Average age of 
all symptomatic patients was 74.5 years old while the average age for asymptomatic patients was 
70. There was no significant difference between the ages of the patients and whether they were 
asymptomatic or symptomatic (Welch’s t-test; p=0.1273) (Figure 4a). The mean of all male 
patients was 74 years old, and the average for all female patients was 71, and there was no 
significant difference between the mean ages of patients relative to their sex (Welch’s t-test; 
p=0.3085) (Figure 4b). The mean age of all patients was 70.8 years old. 68.4% of the patients in 
the study were above the age of 65, and 86% of the patients were above the age of 60. 
 
4.1.2 Patient recruitment samples 
1301 patients were visited during the first 24 hours of their stay at Med4 North and Med6 South 
of HSN. Of the 1301 patients asked to participate in our study, 626 (48%) patients consented to 
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participate while 675 (52%) patients declined. Of the 626 patients that consented to participate, 
220 stool samples were collected, of which 29 (13%) samples were positive for C. difficile by 
culture and were included in this study (Table 4). 
4.1.3 Clinical samples 
31 samples that had tested positive for C. difficile by the GeneXpert from physician ordered tests 
at HSN’s clinical lab were donated to the study. From those 31 samples, 28 samples were 
positive for C. difficile by culture and were included in the study (Table 4). 
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a.  
 
 
 
 
b. 
(a.) There was no significant difference between in age between patients that were asymptomatic 
and the patients that exhibited symptoms in the study. Mean age for symptomatic presentation 
was 74.5 while asymptomatic patients were on average 70 years old (p=0.1273) (b.) This was 
also the case when comparing the ages of male and female patients, with a mean age of 74 for 
males and 71 for females (p=0.3085). 
 
Figure 4 - a. Age of patients vs. patient symptoms   b. Age of patients vs. sex of patients 
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Table 4 - Stool samples received vs. C. difficile positive samples from clinical and consented 
samples 
  Samples received C. difficile positive samples 
Clinical Samples 31 28 
Consented samples 220 29 
Total  251 57 
 
Table 4 shows the samples that were received from the clinical lab and from patients that were 
consented from the Respiratory unit as well as the Oncology and Palliative Care unit. This 
includes all stool samples, and shows is the number of stool samples that were positive for C. 
difficile.  
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4.2 Characterization of C. difficile strains 
4.2.1 Cepheid GeneXpert 
All 220 stool samples from consented patients, as well as the 31 stool samples sent to the clinical 
lab from physician ordered C. difficile testing were first tested on the Cepheid GeneXpert. Of the 
samples that were received from patients that consented to participate in the study, 8 samples 
were negative for tcdB, cdt and tcdC, 19 samples were positive for tcdB, but negative for cdt and 
tcdC, 1 sample was positive for tcdB and cdt, but negative for tcdC, and 1 sample was positive 
for tcdB, cdt and tcdC. We did not receive any clinical samples that were negative for tcdB, cdt 
and tcdC, 22 samples were positive for tcdB but negative for cdt and tcdC, 5 samples were 
positive for tcdB and cdt and negative for tcdC, and finally 1 sample was positive for tcdB, cdt 
and tcdC. At this point, consented and clinical samples were evaluated separately to note the 
number of patients that were carriers, which could only be found in consented patients.  
 
Samples that were positive for tcdB but negative for cdt and tcdC make up 72% of the samples. 
Samples that were negative for tcdB, cdt and tcdC accounted for 14% of the samples. Samples 
positive for tcdB, cdt and negative for tcdC made up 10.5% of the population, while samples 
positive for all accounted for 3.5% of the population (Table 5). This shows that only a small 
portion of the sample population is in fact positive for the binary toxin (14% of samples) while 
the majority of samples would only have the toxins located on the PaLoc. 
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Table 5 - GeneXpert results for clinical and consented samples 
 
 
The GeneXpert results for both samples collected from clinical lab and from consented patients 
are shown in table 5. 72% of samples are found to be tcdB positive, cdt negative and tcdC 
negative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GeneXpert Results Clinical Samples Consented Samples Total  Percentage (%) 
tcdB - / cdt - / tcdC- 0 8 8 14 
tcdB + / cdt - / tcdC- 22 19 41 72 
tcdB + / cdt + / tcdC- 5 1 6 10.5 
tcdB + /cdt+ / tcdC+ 1 1 2 3.5 
Total 28 29 57 100 
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4.2.2 Toxinotyping  
The DNA from all 57 samples that were isolated by culture were characterized for the presence 
potential genes encoding for toxins (Figure 5). From the consented patients group, 4 samples 
were tcdA and tcdB negative, 23 samples were tcdA and tcdB positive, 1 was tcdA positive but 
tcdB negative, and 1 sample contained the tcdA gene truncation. From the samples received from 
the clinical lab, from physician ordered C. difficile test, 1 sample was tcdA and tcdB negative, 22 
samples were tcdA and tcdB positive, 3 samples were tcdA positive but tcdB negative, and 2 
samples contained the tcdA gene truncation. No tcdA negative and tcdB positive samples were 
found.  
 
tcdA and tcdB positive samples accounted for 79% of all samples, while tcdA and tcdB negative 
samples accounted for 9% of all samples. tcdA positive but tcdB negative made up 10.5% of all 
samples, and the samples containing the truncations in the tcdA gene made up 1.5% of all 
samples (Table 6). 
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Table 6 - Toxin expression (tcdA and tcdB) of all stool samples received from patients at 
HSN 
Toxin expression Clinical Samples Consented Samples Total  Percentage (%) 
tcdA- / tcdB- 1 4 5 9 
tcdA + / tcdB + 22 23 45 79 
tcdA + / tcdB - 3 1 4 10.5 
tcdA - / tcdB + 0 0 0 0 
tcdA (del)+ / tcdB + 2 1 3 1.5 
Total 28 29 57 100 
 
 
Table 6 demonstrates the toxin expression (tcdA and tcdB) for samples gathered from the clinical 
lab and from consented patients. 79% of samples were both tcdA positive and tcdB positive 
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Figure 5 depicts the results of the separation of PCR-generated amplicons by agarose gel 
electrophoresis in order to characterize the toxin expression in C. difficile for all samples used in 
the study. The tpi gene is a housekeeping gene that is conserved in all C. difficile strains with a 
unique sequence to the organism and generates a 230bp amplicon. tcdA generates a 369bp 
amplicon, or should the truncation of tcdA be present, it generates an 110bp amplicon. Finally, 
the tcdB gene generates a 160bp amplicon. 
 
 
Figure 5 - Characterization of toxin genes (tcdA and tcdB) among C. difficile isolates from 
patient stool samples at HSN 
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4.2.3 Ribotyping 
Following characterization, ribotyping analysis of all 57 C. difficile DNA samples was 
performed. It was found that there were 26 different ribotypes among the 57 samples, 5 of which 
could not be matched to any other ribotypes in our database (no associated ribotype in database 
(NARD), and 3 ribotypes were previously found to be unique to Sudbury. Ribotypes of the 
samples included 001, 002, 012, 017, 046, 056, 075, 077, 106, 126, 137, 174, 251, M, O, and Z. 
Typical nomenclature of ribotypes are indicated by three numbers, however this is not a 
standard. The ribotypes that were unique to Sudbury are S03677, S0933 and S2319. The most 
common ribotypes are 020 and 106 with 9 and 8 samples, respectively (16% and 14%), followed 
by 001 and 251 with 5 samples each (9%) (Figure 6). There was only one hypervirulent 
NAP1/BI/027. 
 
We were able to correlate the ribotype groups with the toxin expression of each group. Ribotype 
046 and the Sudbury unique strain S0367 were both tcdA and tcdB negative, while ribotypes 001, 
002, 012, 020, 056, 077, 106 137, 174, 251, M, O and Sudbury unique strain S0933 were all tcdA 
and tcdB positive. Ribotypes 027, 075, Z and Sudbury unique strain S2319 were tcdA positive 
but tcdB negative. Finally, ribotypes 017 and 126 were both strains that contain the truncation in 
the tcdA gene (Table 7). 
 
The ribotype groups were divided between the symptomatic and asymptomatic patients to 
observe the distributions of the ribotype groups. Ribotype 106 was found to be almost 
exclusively found among symptomatic patients (88%), as was ribotype 251 (80%), ribotype 001 
(80%), and ribotype 056 (75%). Ribotype 020, which is one of the most common ribotypes at 
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HSN, was found to be distributed almost equally between symptomatic and asymptomatic (45% 
and 55% respectively). All samples which we could not match up to any other ribotype in our 
database (NARD) were found to be asymptomatic. The Sudbury unique ribotype strains S0367 
and S2319 were only found in asymptomatic individuals, while the Sudbury unique ribotype 
strain S0933 was found in a symptomatic individual (Figure 7).  
 
The distribution of ribotype groups between sexes was also observed. The ribotype distribution 
between the two most frequent groups, ribotype 020 and ribotype 106 was fairly close, with 
33.3% in females and 66.7% in males for ribotype 020 and 62.5% in females and 37.5% in males 
for ribotype 106. Ribotype 056 was found predominantly in males (75%), ribotype 001 and 
ribotype 251 were both found to be closely distributed, with 60% of samples found to come from 
males and 40% from females. Ribotype 002 was only found in females.  Ribotype strains unique 
to Sudbury S0367 and S0933 were found only in females, while S2319 came from a male 
(Figure 8). 
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Figure 6 - Ribotypes found among C. difficile isolates from patient samples at HSN 
Representation of all the ribotypes found in patient samples at HSN. The most common 
ribotypes found were 020 and 106 with 8 samples per ribotype. There was fairly large diversity 
of ribotypes found in patients at HSN suggesting that patients are not contracting the organism 
from the same source.  
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Table 7 - Association of the different toxinotype profiles with ribotypes from patient 
samples at HSN 
 
 
Table 7 demonstrates the toxin expression that was found in all the ribotype groups from samples 
of HSN patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Toxin expression Ribotypes 
tcdA - /  tcdB - 046, S0367 
tcdA + /  tcdB - 027, 075, S2319, Z 
tcdA (del) /  tcdB + 017, 126 
tcdA - /  tcdB + 
 tcdA + /  tcdB + 001, 002, 012, 020, 056, 077, 106, 137, 174, 251, M, O, S0933 
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Figure 7 – Distribution of C. difficile ribotypes between symptomatic and asymptomatic 
patients at HSN 
The ribotypes from all the samples were grouped by exhibition of symptoms (i.e. asymptomatic 
or symptomatic) to see if patients were more prone to developing symptoms with certain strains. 
Of interest was ribotype 020 and 106 as the most commonly found ribotypes in patients at HSN. 
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Figure 8 – Distribution of C. difficile ribotypes among male and female patients 
The ribotypes were divided between the sexes to see if infection rates were different between 
males and females.  
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4.3 Biology of C. difficile strains  
4.3.1 Microbial spore load 
The range of the spores that was found in patients stools varied vastly from 196 spores/g of stool 
to 2.6x10
7
 spores/g of stool. The average quantity of spores was found to be 2.4x10
6
 spores/g of 
stool with a median of 119,481 spores/g of stool.  
 
The samples were first divided by symptomatic and asymptomatic. There were no significant 
differences between the groups (p=0.3528). The mean of the symptomatic group was 
1.8x10
6
±6.7x105 spores/g of stool while the mean for the asymptomatic group was 
3.4x10
6
±1.6x10
6 
spores/g of stool. Due to the large variance in the spore load in stool, the 
standard deviation was quite large (Figure 9). 
 
The samples were then grouped by sex. Once again, there were no significant differences 
between the groups (p=0.0870). The mean for the males was found to be 1.2x10
6
±6.1x10
5 
spores/g of stool while the mean for the females was 4.0x10
6
±1.5x10
6
 spores/g of stool. Due to 
the large variance in spore load between all the samples, the standard deviation was quite large 
(Figure 10).  
 
Age was taken into account to see if it played a role in the quantity of spores found in the 
patients’ stool. The ages were divided into groups of 10 years (21-30, 31-40, 41-50, 51-60, 61-
70, 71-80, 81-90, and 91-100). No significant difference was found between the age groups 
(p=0.5803); however, the age group of 71-80 years old had a much larger variation in spore load 
in the stool compared to any other groups (Figure 11).  
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Comparison of the spore load in stools between all the ribotype groups was impossible as only 5 
of the 21 ribotype groups found in patients had 3 samples or more (Figure 12). The 5 ribotype 
groups with more than 3 samples in each were 001, 020, 056, 106, and 251. A comparison of 
those groups revealed that there were no significant differences in spore load between any of the 
groups (p=0.9912) (Figure 13). 
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The average number of spores found in symptomatic patient was 1.8x106 spores/g of stool while 
for asymptomatic it was 3.4x106 spores/g of stool. No significant differences between the groups 
(p=0.3528). (Welch’s t-test) 
 
 
Figure 9 - Microbial spore load (spores/g of stool) found in the stools of symptomatic and 
asymptomatic patients at HSN 
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Figure 10 - Microbial spore load (spores/g of stool) found in the stool of male and female 
patients at HSN 
 
A comparison between the mean of the microbial spore load (spores/g of stool) in male and 
female patients at HSN revealed that there was no significant differences in mean between the 
sexes (p=0.0870). (Welch’s t-test) 
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The microbial spore load in stool (spores/g) of each patient in the study was placed in their 
respective age groups. The ages were divided into groups of 10 years (21-30, 31-40, 41-50, 51-
60, 61-70, 71-80, 81-90, and 91-100). There were no significant differences between the age 
groups (p=0.5803), however it is worthy to note that the 71-80 years old group had a much larger 
variance in quantity of spores in their stool. (One-way ANOVA) 
 
 
 
Figure 11 - Distribution of the microbial spore load in stool (spores/g) within 10 year age 
groups of patients at HSN 
 74 
 
Depicted in figure 12 is the distribution of the microbial spore load in stools (spores/g) across all 
the ribotypes. It was impossible to do any statistical analysis on all the groups as some of the 
groups had fewer than three samples.  
 
 
 
Figure 12 - Distribution of the microbial spore load in stools (spore/g) within ribotype 
groups found in patients at HSN 
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The most commonly found ribotypes in patients at HSN (001, 020, 056, 106, and 251) were 
compared. Due to the great variance in spore load in each of the groups, there were no statistical 
differences between any of them (p=0.9912). (One-way ANOVA) 
 
Figure 13 - Distribution of the microbial spore load in stools (spores/g) within the most 
common ribotype groups found in patients at HSN 
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4.3.2 In vitro toxin production 
As was the case with the microbial spore load, some of the ribotype groups were too small to be 
able to run any statistical analysis. Figure 14 shows the level of toxin produced in each ribotype 
group, while figure 15 shows the level of toxin produced in the most commonly found ribotype 
groups among patients at HSN, namely 001, 020, 056, 106, and 251. Obviously, non-toxigenic 
isolates, namely ribotypes 046 and S0367 produced no toxin. However, certain strains that were 
in ribotype groups 017, 106, and 251 did not produce any toxins, even though they are known to 
contain the PaLoc, and other strains from the same group did produce toxin.  
 
All the samples from ribotype groups 001 and 020 produced relatively the same level of toxins, 
at an average of a dilution factor of 10.37 and 9.30, respectively. Ribotype 020 had some 
variance, ranging from 9.90 to 10.81 with a mean of 10.46. Ribotypes 106 and 251 showed the 
greatest range of variance, both having some isolates that did not produce toxin ranging to a 
dilution factor of 11.46 and 11.19 respectively. There was however no statistical significance 
between any of the ribotype groups (p=0.4330).  
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Toxin levels of all C. difficile strains from patients at HSN were grouped by ribotypes. Because a 
large number of the ribotype groups contained less than three samples, it was impossible to do 
any statistical testing. Known non-toxigenic strains from ribotype group 046 and S0367 did not 
produce any toxins. Conversely, some samples from known toxigenic groups 017, 106 and 251 
did not produce any toxins as they should have.   
Figure 14 - Toxin levels produced (dilution factor) by C. difficile isolates in each ribotype 
group from patients HSN 
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Ribotypes 001, 020, 056, 106 and 251 were compared for their toxin expression. All samples 
from groups 001 and 056 produced toxin with little variance, with an average dilution factor of 
10.4 and 10.5, respectively. Ribotype 020 had more variance in production of toxin, with an 
average dilution factor of 9.3. Ribotypes 106 and 251 had the most variance, and also had strains 
that did not produce any toxin. Their average toxin levels were 7.9 and 8.3, respectively. There 
was no significant difference between each group (p=0.4330). (One-way ANOVA) 
Figure 15 - Toxin level produced (dilution factor) by C. difficile strains in each of the most 
common ribotype groups from patients HSN 
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4.3.3 Classification of patients severity of symptoms 
When the 57 cases in the study were reviewed for the severity of each patient’s symptoms, 23 
(40.3%) of the cases were deemed asymptomatic and as such were given a score of 0. From the 
remaining 34 cases, 22 (38.6%) were mild-to-moderate (1), 11 (19.3%) were severe (2), and only 
1 case (1.8%) was severe and complicated (3). 
 
The severity of the patients’ symptoms was evenly distributed between both males and females; 
with a mean of 0.81±0.14 for the males and 0.85±0.16 for the females. There was no significant 
difference in severity between males and females (p=0.8554) (Figure 16). From the 26 females in 
the study, 10 were asymptomatic (0), 11 were mild-to-moderate (1), 4 were severe (2) and 1 was 
severe and complicated (3). From the 31 males in the study, 13 were asymptomatic (0), 11 were 
mild-to-moderate (1) and 7 were severe (2). 
 
The severity of the patients’ symptoms was analyzed by correlating against the ribotype of the 
isolates. Again, due to the large number of groups and small number of samples within each 
ribotype group, no statistical analysis could be done between all groups. However, the most 
common ribotypes (001, 020, 056, 106, and 251) were analyzed by means of a one-way 
ANOVA. While ribotype 020 did not have any severity cases above mild-to-moderate 1 (and the 
only ribotype group not to have any severity classified above mild-to-moderate), there was no 
significant difference between the ribotypes and the severity of symptoms they cause (p=0.2209) 
(Figure 17). 
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Microbial spore load was examined in contrast of the severity of symptoms exhibited by the 
patients. Asymptomatic patients had the greatest variance in spore count, ranging from 2169 
spores/g of stool to 2.6x10
7
 spores/g of stool. While this was interesting to note, there were no 
significant differences between the severity of symptoms and the microbial spore load 
(p=0.7802) (Figure 18). 
 
Finally, the level of toxin that each strain is able to produce was analyzed against the severity of 
symptoms shown in patients. In this case, there were also no significant differences between each 
severity group, including the asymptomatic group (p=0.4230). It was found that while patients 
may not have exhibited any symptoms, asymptomatic patients often have stains that produce 
equal levels of toxins as patients who are showing symptoms, anywhere from mild-to-moderate 
to severe and complicated. The average mean of toxin produced was 7.0 in asymptomatic, 8.9 in 
mild-to-moderate, 8.4 in severe, and 8.9 in severe and complicated (Figure 19). 
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Of the 31 males in the study, 13 were asymptomatic (0), 11 were mild-to-moderate (1) and 7 
were severe (2). Of the 26 females in the study, 10 were asymptomatic (0), 11 were mild-to-
moderate (1), 4 were severe (2) and 1 was severe and complicated (3). There was no significant 
difference between the two groups (p=0.8554). (Welch’s t-test) 
 
 
 
Figure 16 - Severity of patient symptoms distributed between sexes 
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To see if isolates of certain ribotypes affect the severity of the infection, we assessed for 
association between the severity of symptoms and the most commonly found ribotypes at HSN. 
Each of the ribotype groups were also found among asymptomatic patients. Ribotype 020 did not 
cause more than mild-to-moderate symptoms in patients (1), while the other ribotype groups 
were isolated from patients experiencing severe symptoms (2), and none was involved in severe 
and complicated cases (3). No significant difference was found between ribotype groups 
(p=0.2209). (One-way ANOVA) 
Figure 17 - Severity of the symptoms exhibited by patients do not correlate with the 
ribotype strain infecting them. 
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The greatest variance in microbial spore load was found in asymptomatic patients, where the 
spore load ranged from 2169 spores/g of stool to 2.6x10
7
 spores/g of stool. However, there was 
no significant difference between the severity of the patients’ symptoms and the microbial spore 
load found in their stools (p=0.7802). (One-way ANOVA) 
 
 
Figure 18 - Microbial spore load (spores/g of stool) found in each category of severity of 
symptoms exhibited by patients 
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Toxigenic C. difficile strains are often found in asymptomatic patients, and as can be seen in 
figure 19, the asymptomatic patients in the study were colonized with toxigenic strains in many 
cases. While the average toxin levels in asymptomatic patients are lower (7.0) than the 
symptomatic patients (8.9 in mild-to-moderate (1), 8.4 in severe (2), and 8.9 in severe and 
complicated (3) there was no significant difference in the ability of isolates between severity 
groups  to produce toxin (p=0.4230). (One-way ANOVA) 
Figure 19 - Toxin levels (dilution factor) produced by C. difficile isolates among patients 
exhibiting different levels of severity of CDI associated symptoms. 
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4.3.4 Antibiotic susceptibility 
4.3.4.1 Vancomycin 
The population distribution of vancomycin resistance closely resembles that of EUCAST. The 
MIC50 was found to be 0.5mg/L, and the MIC90 was 2mg/L. The epidemiological cut-off 
(ECOFF) of vancomycin resistance is 2mg/L, and no strain was found to be over this cut-off 
point, meaning that all strains were found to be susceptible to vancomycin. Population 
distribution of vancomycin was comparable to that of EUCAST, with EUCAST MIC50 being 
0.5mg/L, and MIC90 being 1mg/L (Figure 20).  
 
4.3.4.2 Metronidazole 
Metronidazole antibiogram profile showed a bimodal distribution. The MIC50 was found to be 
2mg/L and the MIC90 was >256mg/L, while the EUCAST MIC50is 0.25mg/L and MIC90 is 
1mg/L. 34 (61%) isolates were susceptible to metronidazole, while 22 (39%) were resistant 
(ECOFF 2mg/L). The EUCAST distribution was of lower MIC values, with only about 1% of 
the reported strains being resistant to metronidazole (ECOFF 2mg/L). 8 of the resistant strains 
were unaffected by metronidazole, and a zone of inhibition was completely absent in these 
strains (Figure 21).  
 
4.3.4.3 Clindamycin 
Clindamycin data did not show a typical normal distribution, and the data was fairly scattered. 
MIC50 was found to be 0.25mg/L, while MIC90 was found to be 64mg/L compared to 
EUCAST’s MIC50 being 4mg/L and MIC90 at 256mg/L. The ECOFF was set to 16mg/L by 
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EUCAST, meaning that 50 out of the 57 strains tested (87.5%) were susceptible to clindamycin 
and 7 (12.5%) were resistant. Five strains (9%) were completely resistant to the E-test strip with 
a maximum MIC value of 256mg/L and did not show any zone of inhibition (Figure 22).  
 
4.3.4.4 Ciprofloxacin 
All 57 strains tested against ciprofloxacin were found to be resistant to the antibiotic. The MIC50 
and MIC 90 were both >32mg/L, with the EUCAST MIC50 and MIC90 at 64mg/L (Figure 23). 
It was expected that all the strains would be resistant to ciprofloxacin as Norfloxacin was used in 
the CDSA media, and therefore any organism that grew on the media would have to be resistant 
to quinolones. This also shows the robustness of the C. difficile isolation method we used as no 
norfloxacin-sensitive colonies were found.  
 
4.3.4.5 Amoxicillin 
The MIC50 of HSN strains was found to be 0.125mg/L while the MIC90 was 0.5mg/L, which is 
lower than the EUCAST MIC50 (1mg/L) and MIC90 (2mg/L) suggesting that the strains found 
at HSN are slightly more susceptible than that in other regions. The MIC distribution for the 
HSN strains was skewed slightly to the right, while the EUCAST data skewed more towards the 
left. Unfortunately, EUCAST did not have an ECOFF value for amoxicillin; therefore, it is 
impossible to identify a concentration above which the cells exhibit resistance to amoxicillin 
(Figure 24). 
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4.3.4.6 Benzyl Penicillin 
Similar to amoxicillin, the susceptibility to benzyl penicillin is slightly greater in the strains 
collected at HSN than they are in the data collected by EUCAST. The MIC50 for the HSN 
strains was 1mg/L and the MIC90 was 2mg/L, while in the EUCAST data the MIC50 was 1mg/L 
and the MIC90 was 4mg/L. EUCAST did not provide an ECOFF value, therefore we cannot 
determine the rate of the resistant isolates (Figure 25).  
 
4.3.4.7 Cefotaxime 
There was no data gathered by EUCAST for cefotaxime; therefore, there is no population data 
from which trends can be observed.  Since no ECOFF was determined, we cannot conclude 
which isolates are indeed susceptible or resistant. However, we did determine that the MIC50 
and the MIC90 of the HSN strains to cefotaxime to be >256mg/L, with 30 of the strains (54%) 
having no zone of inhibition, even at the maximum dosage for the E-test strips (Figure 26).  
 
4.3.4.8 Imipenem 
As was the case with cefotaxime, EUCAST has no data regarding antibiotic susceptibility of C. 
difficile to imipenem. The MIC 50 was found to be 4mg/L and the MIC90 16mg/L. 5 strains 
(9%) had no zone of inhibition at the maximum concentration of the E-test strip (32mg/L) 
(Figure 27). 
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Figure 20 - MIC distribution for vancomycin susceptibility among C. difficile isolates found 
in patients at HSN 
ECOFF for vancomycin as described by EUCAST is 2mg/L. All strains collected at HSN were 
susceptible to vancomycin, with a MIC50 of 0.5mg/L and a MIC90 of 2mg/L. The population 
distribution at HSN closely resembles the global population collected by EUCAST. 
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Figure 21 - MIC distribution for metronidazole susceptibility among C. difficile isolates 
found in patients at HSN 
ECOFF for metronidazole as described by EUCAST is 2mg/L. The MIC value distribution for 
metronidazole susceptibility of C. difficile isolates at HSN shows trimodal with susceptible 
isolates below the 2mg/L, and resistant isolates above the 2mg/L line. 22 isolates were found to 
be resistant to metronidazole, with 14% being unaffected by highest concentration of 
metronidazole on the E-test strips. 
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Figure 22 - MIC distribution for clindamycin susceptibility among C. difficile isolates found 
in patients at HSN 
ECOFF for clindamycin as described by EUCAST is 16mg/L. The C. difficile isolates all reacted 
very differently to clindamycin, with 50 out of the 57 strains tested being susceptible and 7 
strains being resistant.  
 
 
11 
16 
7 
11 
9 
4 
9 
18 
2 2 
0 0 
4 
0 0 
9 
0 0 0 0 
1 
4 
9 
21 
27 
16 
2 
0 0 0 
7 
10 
0
5
10
15
20
25
30
P
e
rc
e
n
ta
ge
 o
f 
is
o
la
te
s 
MIC (mg/L) 
HSN Patients
EUCAST
 91 
 
 
Figure 23 - MIC distribution for ciprofloxacin susceptibility among C. difficile isolates 
found in patients at HSN 
No ECOFF was described for ciprofloxacin by EUCAST. However, none of the strains were 
affected by the E-test strips, and no zones of inhibition were recorded at 32mg/L.  
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Figure 24 - MIC distribution for amoxicillin susceptibility among C. difficile isolates found 
in patients at HSN  
No ECOFF was described for amoxicillin by EUCAST. The MIC50 (0.125mg/L) and MIC90 
(0.5mg/L) were both found to be lower than the global population as collected by EUCAST 
(1mg/L and 2mg/L respectively).  
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Figure 25 - MIC distribution for benzyl penicillin susceptibility among C. difficile isolates 
found in patients at HSN 
No ECOFF was described for benzyl penicillin by EUCAST. The population distribution of 
susceptibility to benzyl penicillin is slightly greater at HSN than it is globally; the MIC50 was 
1mg/L and MIC90 was 2mg/L at HSN compared to 1mg/L and 4mg/L respectively. 
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Figure 26 - MIC distribution for cefotaxime susceptibility among C. difficile isolates found 
in patients at HSN 
No ECOFF was described for cefotaxime by EUCAST, nor was there data gathered. The 
majority of strains were unaffected by the E-test strip at a dosage of 256mg/L, suggesting that 
the strains are resistant to the antibiotic.  
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Figure 27 - MIC distribution for imipenem susceptibility among C. difficile isolates found 
in patients at HSN 
No ECOFF was described for imipenem by EUCAST, nor was there data gathered. 9% of the 
strains were unaffected by the E-test strips at a dosage of 32mg/L. The MIC50 was found to be 
4mg/L, and the MIC90 was 16mg/L.  
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4.3.4.9 Summary of antibiotic susceptibility comparison between HSN isolates and 
EUCAST 
Following the comparisons between the isolates from HSN patients and EUCAST data, we can 
see that the HSN strains are less sensitive to metronidazole than the data given by EUCAST, 
equally sensitive to benzyl penicillin, vancomycin and ciprofloxacin, and more sensitive to 
clindamycin and amoxicillin.  
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5.0 Discussion 
5.1 Sample processing and patient demographics 
While being in an acute teaching hospital is a prime location for acquiring patient samples for C. 
difficile, we decided to only consent patients from two units at the hospital: the respiratory unit 
and the oncology and palliative care unit. These two wards were picked based on the number 
CDI reports which had occurred in recent months, as well as their high rate of 
hospitalization[67]. This, however, significantly lowered the number of opportunities to meet 
people who may be asymptomatic carriers. Furthermore, 1301 patients were approached to 
consent to participate in the study, and 626 (48%) of them agreed to participate. This already 
lowered the odds by more than 50%. Only about a third of those patients were able to provide a 
stool sample before being discharged (220 stool samples), and of those only 29 samples (13%) 
were positive for C. difficile. This is not a surprising rate, as it has been reported by several 
different studies that the carriage rate of C. difficile in healthy individuals in anywhere between 5 
and 15% [9]. Unfortunately, one of the drawbacks to the rate of carriage in the study is that it 
involves only people who are admitted to the hospital. The two targeted wards (the respiratory 
disease and oncology wards) tend to have an older population; indeed, it was very rare that we 
met patients that were aged 50 or younger (three cases only). This left us quite in the dark in 
terms of rate of carriage in a population younger than 50 years old.  
 
Medical waste samples received from HSN’s clinical lab which were used in the study were 
procured during the period of patient consenting (November 2013 to July 2015), reducing the 
number of samples that we could use as we had received over 300 samples since the beginning 
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of the C. difficile projects in 2012. Future plans to restart accrual of patients to include all wards 
of the hospital over a greater period of time are in the works to overcome some of the 
shortcomings of this project.  
 
The average age of all patients that participated in the study was 70.8 years old, and the average 
age of patients with symptomatic CDI was 74.5 years old. Between 2007 and 2012, the Public 
Health Agency of Canada reported the average age of patients with CDI for every year of the 
report, which ranged from 69.4 years old to 70.7 years old (Table 1) [6]. The patients who were 
colonized with C. difficile at HSN are close to that age range, albeit a bit older. As mentioned, 
one of the major risk factors to developing CDI is age, with a sharp increase in incidence for 
people over the age of 65 [1], [2], [18]. Indeed, 68.4% of the patients in the study were above the 
age of 65, and 86% of the patients were above the age of 60.  
 
There were no significant differences found in age between the symptomatic patients and the 
asymptomatic patients (Figure 4a). While one would suspect that the age of the symptomatic 
patients would be greater than that of the asymptomatic patients, this may have been due to the 
fact that the majority of hospitalized patients are of older ages. It is a fair assumption that should 
members of the community in all age groups be included in a similar study, we might see a 
lowered age mean [68]. There were also no significant differences between the average age of 
patients between males and females. There have been some research focused on sex bias of C. 
difficile infections [69]. It is known that females exhibit stronger humoral and cell-mediate 
immune responses, however, this tends to change after menopause leading researchers to believe 
that this phenomenon is due to the variation in sex hormones between males and females [70]. 
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Women tend to have a more robust immune response and this is partially attributed to estrogen. 
Estradiol hormones are considered to be more enhancing towards the immune system, while 
testosterone is found to be more immunosuppressive [70], [71]. During menopause, women’s 
levels of estrogen drops considerably and no longer have an enhancing effect on the immune 
system [71]. Considering that most CDI cases are post-menopause, it is therefore not surprising 
that there is no sex discrimination in CDI.  
 
5.2 Characterization of C. difficile strains 
At HSN, the Cepheid GeneXpert platform is used for laboratory diagnostic testing of stool 
samples for C. difficile and other diseases. The GeneXpert, a real-time PCR-based instrument 
comes with ready-to-run cartridges that only need the stool sample to be homogenized in a bottle 
of pre-packaged reagents before being loaded into the cartridge [63]. This method of testing for 
C. difficile infection replaced conventional EIA in 2012 as the primary way of analyzing stool 
samples. The real-time PCR method detected higher rates of CDI in patients than the EIA 
method [61], and has the advantage of determining whether an isolate  may be the hypervirulent 
strain NAP1/BI/027 by being able to detect the presence of cdt and a deletion at nucleotide 117 
of the tcdC gene. 72% of the stool samples (41 samples) were only tcdB positive, with 14% of 
the samples (8 samples) being positive for cdt.  
 
Most of the research has focused on tcdA and tcdB, and cdt was certainly overlooked. It only 
came into prominence when it was discovered as an additional virulence factor present in the 
hypervirulent strain NAP1/BI/027 in the early 2000s [24]. Even in this study, other than knowing 
whether it was present due to the GeneXpert results, no other work was performed in relation to 
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cdt. This I believe to be a gap in C. difficile research, one that will be filled as more and more 
researchers are becoming aware of the damage it can potentially do to its host [24]. It is known 
that the expression of binary toxin (cdt) contributes to the increased morbidity resulting in 
prolonged length of hospital stay [24].  
 
Fourteen percent of stool samples (8 samples) were negative for all three criteria on the 
GeneXpert, but were found to be positive by culture. This means that the GeneXpert was unable 
to detect all patients colonized with C. difficile. The GeneXpert has certain disadvantages; while 
the rapidity of the test helps in quickly determining if a patient is C. difficile-positive to change 
the course of his or her treatment, certain strains are missed altogether, giving false negative 
results.  This could have detrimental effects on such patients. A big factor in why 14 stool 
samples were negative by GeneXpert is most likely because all asymptomatic patients would not 
have been tested due to not meeting the criteria for CDI. Another possible reason for this is that 
the low levels of C. difficile may have fallen under the detection limit of the instrument [72]. 
Furthermore, some strains may have not met the criteria of the test; 4 of the strains in the study 
are tcdA positive but tcdB negative. Should those strains be cdt negative and not contain the 
deletion at nucleotide 117 of the tcdC, they would be missed altogether by the instrument. The 
false negative rate of the GeneXpert over a larger number of samples and longer period of study 
was found to be 2.2%, which is still considered a relatively low rate of failure [72]. Using 
primers for a gene such as tpi could help identify all cases of colonized C. difficile patients. 
 
Characterizing C. difficile strains for toxin expression is important, especially for determining the 
presence of the PaLoc [64]. The absence of PaLoc accounts for many of the asymptomatic cases 
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of C. difficile colonization, but not all. Eighteen out of the 23 asymptomatic patients were 
colonized with toxigenic C. difficile putting them at risk of developing CDI should a course of 
broad-spectrum antibiotics be started. With this knowledge in hand, a physician could decide on 
a course of antibiotics that is also detrimental to C. difficile, such as metronidazole or 
vancomycin. However, toxin expression is not a standard clinical laboratory test; furthermore, it 
is conducted using the chromosomal DNA of cultured C. difficile cells, which takes 5 to 7 days 
to grow.  This could be too late for use in patient management.   
 
Seventy nine percent of the C. difficile isolates in the study were tcdA and tcdB positive. 9% 
were tcdA and tcdB negative, and 10.5% were tcdA positive and tcdB negative. A very small 
portion of the population (1.5%) contained the truncation in the tcdA gene. With 91% of the 
isolates known to be toxigenic, and only 60% of the study population showing symptoms of 
CDI, it is clear as to why knowing the toxin expression could help in prevention of the infection. 
To avoid this problem, the best course of action would be to test each patient that is a potential 
candidate for antibiotic therapy for C. difficile colonization (using conventional testing means i.e. 
GeneXpert at HSN), giving the physicians a more complete picture when choosing which 
antibiotic to treat their patients with.  
 
Ribotyping has become a gold standard in epidemiological studies and in the classification of C. 
difficile. This method is fast, reliable, inexpensive and highly reproducible. The most frequent 
ribotypes at HSN found in this study were 020 and 106, which is consistent with previous results 
on the epidemiology of C. difficile  at HSN [67]. Ribotype 020, with the highest frequency (9 
cases, 15.8%), was distributed fairly evenly between symptomatic and asymptomatic patients. A 
 102 
 
recent study has found that ribotype 020, a frequent strain in humans, is also found in different 
animals (such as cattle) and in water [17]. This could explain why it is a very common strain 
affecting humans worldwide [17]. As for ribotype 106, its presence was predominantly in 
symptomatic patients. This ribotype is also found in hospitals in England, and is one of the most 
predominant strains in the UK. It was described as being the second most frequently found strain 
at the District General Hospital in South East England after ribotype 027. It was found to cause 
severe CDI in 78% of CDI cases, and a mortality rate of 10.8% [73]. It is also important to note 
that prior work done at HSNRI had found a significantly high frequency of hypervirulent 
NAP1/BI/027 strain, which was the third most prominent strain infecting patients at HSN  [67]. 
In this study, only one case of NAP1/BI/027 was found.  
 
From our previous C. difficile study at HSNRI, we also discovered several new ribotypes that 
were unique to HSN. Ribotypes S0367, S0933 and S2319 were present in this study as well. The 
only Sudbury-specific isolate that was found in a symptomatic patient was S0933, which is also 
toxigenic. The fact that there are C. difficile isolates that are unique to Sudbury is very 
interesting, as it shows the existence of a large diversity among C. difficile. Furthermore, there 
are another 5 isolates that we could not match up to any other ribotype in our database (no 
associated ribotype in database, NARD). However, further testing on those isolates at another 
facility with a much larger database would corroborate whether they are indeed previously 
unidentified strains.  
 
As part of our study, we wanted to see if there was a bias for ribotypes between sexes brought on 
by the sexual dimorphism in immune system between males and females as mentioned before in 
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the discussion. Unfortunately, the biggest problem with using ribotypes as a form of 
classification is the fact that there are over 300 different ribotypes described thus far [17]. This is 
quite problematic considering the rather small sample size that this study has compared the 
number of ribotype groups available. Many isolates found were isolated only once in a ribotype 
group, resulting in group sizes being too small for any statistical analyses. As mentioned, 
sequence-based methods are now becoming more accessible and much cheaper, and many 
researchers are slowly transitioning to that method of classification [15]. A classification system 
that is coming to prominence uses sequence-based classification to classify the C. difficile 
population into 6 phylogenetic clades (1, 2, 3, 4, 5 and C-I). This much smaller grouping system 
would benefit research greatly as the isolates are grouped in similarity of their genetic sequence, 
which would associate like with like as opposed to arbitrary grouping based on intergenic spacer 
regions. 
  
5.3 Biology of C. difficile strains 
5.3.1 Microbial spore load 
Sporulation is an intricate microbial process that C. difficile employs to survive in harsh 
environments such as an aerobic environment or nutritional stress. Additionally, the spores are 
thought to be crucial for transmission from host-to-host [18], [37]–[39], [42]. It is for these 
reasons that we thought that we would find more spores in asymptomatic patients; since C. 
difficile isn’t thriving in the colon, it would make sense it would sporulate more to propagate to 
other hosts. While we did see an elevated level of spore count among asymptomatic patients, 
there were no significant differences between the symptomatic and asymptomatic patients stool 
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samples (Figure 9). We also compared stool spore counts between males and females and 
between symptomatic and asymptomatic patients. There was a larger range in the spore count in 
females than there was in males, but still there was no significant difference between the two 
groups (Figure 10). When the patients were divided up in age groups of 10 years apart, the age 
range that had the greatest variance in spore load was the 71-80 year group (Figure 11). There 
was also no significant difference between the spore counts in the stools of patients of different 
age groups, which may be due to the small sample size.  
 
The association of spore count with different ribotypes was investigated. Because of the large 
number of ribotypes, it was hard to discern if there was any one ribotype that produced more 
spores than any other. Because so many of the ribotype groups had lesser than three samples in 
each group, no statistical analyses could be performed (Figure 12). We thus decided to restrict 
our examination to ribotype groups that had more than three samples.  Only 5 of the groups had 
3 or more samples (ribotypes 001, 020, 056, 106, and 251). Each of the 5 groups had a very large 
variation in spore counts in the stool. Due to these large variances, we could not find any 
significant differences between the groups in spore count (Figure 13).  
 
Spore count in stool may not be a relevant way of testing how effective a strain is at propagating 
itself. Firstly, the location and the size of the infection in the colon would both affect the number 
of spores in the stool. A smaller infection would logically have fewer spores as there are fewer 
vegetative cells. Secondly, the stage of progression of the infection would also affect the number 
of spores in the stool. If an infection has been persisting for a few days, it is more likely to have 
more spores in the stool than a new infection from newly colonized C. difficile. The effects of the 
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human immune system are also not being taken into consideration when doing a raw spore count. 
To have a better idea of how well the microorganism is at propagating itself, the spore count 
would need to be normalized against a vegetative cell count in stool. This can prove quite 
problematic as the cells die off quite quickly once exposed to oxygen; depending on the 
environment (dry vs moist).  Vegetative cells usually die off within 15 minutes but can survive 
up to 9 hours [55], [74]. Furthermore, considering the number of different types of bacteria found 
in the human digestive tract and therefore in the stool, a selective and differential media would 
need to be used on stool that is relatively fresh. 
 
5.3.2 In vitro toxin production 
Unfortunately, due to the nature of the sampling and the time that elapsed before any test in this 
study was run, we could not test the toxin content of the stool samples. When stool samples are 
frozen, the toxin titres drop down significantly by day five [75]. When we tried to test the stools 
for toxin, we could not get a reading on the EIA test (data not shown). We still wanted to know 
how much toxin each strain could potentially produce, and to see if certain ribotypes could 
produce more or less toxin. It is already known that the NAP1/BI/027 produces 16 to 23 times 
more toxin than other PFGE types [73]. Again, due to the small number of samples in certain 
ribotypes, we could not perform any meaningful statistical analyses related to toxin production 
and ribotype.  
 
In the most frequent ribotypes (001, 020, 056, 106 and 251), there were no significant difference 
in the level of toxin produced between different ribotype groups (Figure 15). There was very 
little difference between ribotypes 001 and 056. Ribotypes 106 and 251 however had a large 
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degree of variance, with both of these ribotypes having a sample that did not produce any toxin 
at all. Both ribotypes however were positive for PaLoc. Furthermore, each one of the strains was 
cultured on 3 separate occasions and the samples still did not yield any toxin. While this may be 
attributed to environmental and growing conditions, all other strains positive for the PaLoc grew 
and produced toxin. A whole-genome sequencing analysis may reveal if there is a mutation in 
the PaLoc that interferes with toxin production.  
 
5.4 Classification of patients’ symptom severity 
Following the guidelines set by SHEA and IDSA, the severity of the symptoms from each patient 
in the study were identified. From the 57 samples of C. difficile that were in this study, only one 
patient was in the severity index 3 – severe and complicated. One of the key features of a 
severity index 3 is that patients are often in the intensive care unit as their symptoms are so 
severe. Since a large portion of the clinical samples and all of the consented patient samples 
came from the respiratory and the oncology wards, it is surprising that we did not have more 
severity index 3 patients. Linking the severity of the symptoms with the biology of C. difficile 
was key to this project. While describing characteristics of the bacteria is useful information, 
seeing how the biology affects the patient would lead to better CDI patient management in the 
future.  
 
It did not appear that the sex of the patient affected the severity of the symptoms; symptom 
severity was distributed fairly evenly in both males and females (Figure 16). There is little 
evidence in the literature that sex plays a major role in the severity and the outcome of CDI [1], 
[69]. There was no evidence to suggest that strains from a specific ribotype group affected the 
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severity of symptoms in one type of patient than another (Figure 17). While it was quite 
interesting to note that no strain from ribotype 020 caused symptoms more severe than mild-to-
moderate, there is nothing to suggest that it could not. Moreover, each of the other ribotypes (i.e. 
001, 056, 106 and 251) were found in asymptomatic patients, as well as in patients with mild-to-
moderate (1) CDI and severe (2) CDI. Other than non-toxigenic strains, it is impossible to 
predict the severity of the symptoms based on ribotype [76].  As was the case with asymptomatic 
and symptomatic patients, there was no significant difference between microbial spore load and 
severity of infection (Figure 18). Lastly, the potential levels of toxin that each isolate could 
produce did not affect the severity of the symptoms in patients. Stains that were high toxin 
producers were found in asymptomatic patients, and low toxin producing strains were found in 
patients with severe (2) CDI.  For further studies, it would be useful to compare the level of toxin 
in patient stool to the severity of infection in patients to confirm this lack of relationship between 
ribotype and both toxin load and severity of infection.  
 
5.5 Antibiotic susceptibility 
The data available for susceptibility breakpoints for C. difficile is surprisingly low. Only 3 of the 
antibiotics used for this part of the project (vancomycin, metronidazole and clindamycin) had 
defined epidemiological cut-offs (ECOFF). These breakpoints are determined by the European 
Committee on Antimicrobial Susceptibility Testing (EUCAST) or the Clinical and Laboratory 
Standards Institute (CLSI). There are two types of breakpoints defined: wild-type breakpoints 
and clinical breakpoints.  
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Wild-type breakpoints are determined from bacteria that have acquired resistance to a certain 
antibiotic. In the case of C. difficile, fluoroquinolone breakpoints would be considered wild-type 
breakpoints as C. difficile has acquired the gene for resistance to that type of antibiotics. Those 
cases are fairly easy to identify as there is little to no effect from the antibiotic during the test, 
leaving little to no zones of inhibition. Nowadays with whole-genome sequencing, it is easy to 
tell if indeed the organism has acquired an antibiotic resistance gene or genes, though it is not 
always clear if resistance is due to one gene or from a polygenic phenotype. Clinical breakpoints 
are harder to determine and require a large set of data to be able to derive the breakpoint. That is 
because the clinical breakpoints separate the strains based on their likelihood of killing by 
antibiotic treatment. Therefore in order to determine these breakpoints, data not only needs to 
include the MIC, but also the success or failure rate of antibiotic therapy [77]. For this reason, 
without breakpoints from such agencies as EUCAST and CLSI, we cannot say whether or not C. 
difficile is susceptible or resistant to a certain antibiotic; we can only report the trends observed. 
 
EUCAST had no data compiled for either cefotaxime or imipenem. 54% of the strains tested 
against cefotaxime had no zone of inhibition at the maximal dosage of 256mg/L, suggesting that 
there might be an antibiotic resistance that was acquired in certain strains. This was also the case 
for imipenem, 9% of the strains had no zone of inhibition at the maximal dosage of 32mg/L. 
 
Amoxicillin and benzyl penicillin did not have any ECOFF defined by EUCAST; they are 
however compiling data for these two antibiotics. In both cases, the HSN population distribution 
appeared to be more susceptible than the global population gathered by EUCAST. The MIC50 
and MIC90 were both lower than that reported by EUCAST. 
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Ciprofloxacin does not have an ECOFF defined by EUCAST. Ciprofloxacin is a 
fluoroquinolone, and C. difficile has an antibiotic resistance mechanism to fluoroquinolones, so it 
was not surprising that 100% of the strains had no zones of inhibition at the maximal dosage of 
32mg/L [47]. Conversely, all strains were susceptible to vancomycin, which is the antibiotic used 
to treat CDI when metronidazole fails [1].  
 
The results for clindamycin were the most erratic from all the antibiotics tested; there were no 
discernable trends observed, and 7 of the 57 (13%) isolates were resistant to the antibiotic.  
 
The levels of susceptibility and resistance in C. difficile seen might be due to the frequency of 
use of the antibiotics at HSN versus elsewhere in the world. Metronidazole, under the name of 
Flagyl, was found to be given quite frequently to patients visiting the Respiratory unit and 
Oncology and Palliative care unit. Clindamycin and amoxicillin were found to be of lower use on 
those floors.  
 
The most concerning results from the antibiotic susceptibility testing involved treatment with 
metronidazole. 22 isolates out of the 57 (38.5%) tested were found to be resistant to 
metronidazole. Moreover, 8 of those isolates were unaffected by the metronidazole and had no 
zone of inhibition, again suggesting that they may have acquired a gene for resistance to 
metronidazole. This is very concerning considering that metronidazole is the first line of 
treatment for CDI [9]. Based on these numbers, almost 40% of metronidazole treatments for CDI 
at HSN are likely to fail, resulting in persistence of disease. Knowing which isolates are resistant 
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to metronidazole ahead of treatment would benefit the patient in that they could be treated with 
vancomycin immediately and avoid the prolonged illness. In order to do this, antibiotic 
susceptibility testing in the means of E-test would need to be done to every patient strain.  
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6.0 Concluding remarks 
Based on the research conducted in this study, we cannot find any evidence that we can predict 
the severity of symptoms that will be exhibited in patients based solely on certain genotypic and 
phenotypic characteristics of C. difficile such as toxin and spore production. The severity of the 
symptoms is likely due to a combination of bacterial characteristics and the patients’ capability at 
mounting an immune response, and on the co-morbidities that may have an effect on the course 
of their illnesses.  
 
It appears that ribotyping, while being quite a convenient and easy method of classifying strains 
of C. difficile, is not a very practical way of classifying the organism for the severity of infection. 
There are far too many groups, with often too little variance between each group. Ribotyping is, 
nevertheless, a well-established method of strain classification in epidemiological studies.   
 
Finally, results for antibiotic susceptibility were especially concerning for metronidazole. 38.5% 
of isolates were found to be resistant to this first line of treatment antibiotic, likely jeopardizing 
the recovery of patients and prolonging their illness. 
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Appendix II: Database results 
Sample 
ID 
Age Sex Symptoms 
Severity 
index 
GeneXpert Characterization 1 
Rybotype 
Spore count 
in stool 
(spore/g) 
Toxin 
production 
Antibiotic 
Susceptibility 
Toxin B 
Binary 
toxin 
TcdC tpi Tox A Tox B Tox Adel CM VA MZ CI 
CD2586 79 M S 1 + + - + - + + 126 1613861 7.189824559 R S R R 
CD2595 61 M S 1 + - - + + + - 106 8219 11.19401808 R S R R 
CD2597 68 M S 2 + - - + + + - 056 90698 9.897845456 R S R R 
CD2598 81 M S 2 + + - + + - - 075 581 6.270528942 R S R R 
CD2599 79 M S 2 + + - + - + + 126 11304 7.388878339 S S R R 
CD2600 55 M S 2 + - - + + + - 251 119481 9.632995197 R S R R 
CD2601 71 F S 2 + - - + + + - 251 281405 3.201633861 R S R R 
CD2602 55 M S 1 + - - + + + - 106 103448 10.50263294 R S R R 
CD2603 61 M S 1 + - - + + + - 077 330973 4.655351829 R S R R 
CD2604 80 F S 1 + - - + + + - 001 5232143 10.64421682 R S R R 
CD2611 60 M S 1 + - - + + + - 106 2734 5.472487771 R S R R 
CD2613 68 F S 1 + - - + + + - M 304 13.57478272 R S R R 
CD2615 84 F S 2 + + + + + - - 027 147305 12.13955135 R S R R 
CD2623 71 F S 1 + - - + + + - 106 480088 11.46066066 R S R R 
CD2626 80 M S 1 + - - + + + - 020 196 7.852997588 R S R R 
CD2628 98 F S 1 + + - + + - - 075 512 9.590961241 R S R R 
CD2629 84 F S 2 + - - + + + - 106 1026764 6.655351829 R S R R 
CD2630 89 F S 1 + - - + + + - 106 1192771 10.36632221 R S R R 
CD2631 57 M S 1 + - - + + + - 056 1525745 10.81634371 R S R R 
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Appendix II: Database results (Continued) 
 
 
 
 
Sample ID Age Sex Symptoms 
Severity 
index 
GeneXpert Characterization 1 
Rybotype Spore count 
in stool 
(spore/g) 
Toxin 
production 
Antibiotic 
Susceptibility 
Toxin B 
Binary 
toxin 
TcdC tpi Tox A Tox B Tox Adel CM VA MZ CI 
CD2632 84 M S 2 + - - + + + - 174 6643 10.89299809 R S R R 
CD2633 61 M S 1 + - - + + + - 251 25000 6.944858446 R S R R 
CD2634 61 M S 1 + - - + + + - 251 2368 10.04001568 R S R R 
CD2636 81 M S 2 + - - + + + - 001 15323944 10.47613863 R S R R 
CD2637 80 F S 1 + - - + + + - 020 187540 9.559185866 R S R R 
CD2640 65 F S 3 + - - + + + - 002 2085271 8.938991439 R S R R 
CD2641 79 F S 1 + + - + - - - 056 12211302 10.76752239 R S R R 
CD2642 44 F S 1 + - - + + + - 001 1227848 9.569096095 R S R R 
CD2644 71 F S 2 + - - + + + - 106 6000 9.285402219 R S R R 
CDST0007 89 M A 0 + - - + + + - 020 12147 9.553053253 R S R R 
CDST0011 63 F A 0 - - - + - - - S0367 13943 0 R S R R 
CDST0055 89 F S 1 - - - + + + - S0933 2083 9.742140985 R S R R 
CDST0138 61 F A 0 + + + + + + - 251 11582090 10.77082905 R S R R 
CDST0160 86 M S 1 + - - + + + - 020 93277 10.54457812 R S R R 
CDST0185 82 M A 0 + - - + + + - 137 14880 13.56985561 R S R R 
CDST0214 58 F A 0 + - - + + + - NASD 5696 9.777419716 R S R R 
CDST0217 64 F A 0 + - - + + + - NASD 17039 11.00450139 R S R R 
CDST0278 81 M A 0 - - - + - - - NASD 175000 0 R S R R 
CDST0303 78 F S 1 + - - + + + - 012 13297491 4.378511623 R S R R 
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Appendix II: Database results (Continued) 
 
Legend 
M: Male F: Female A: Asymptomatic S: Symptomatic 
CM: Clindamycin VA: Vancomycin MZ: Metronidazole CI: Ciprofloxacin 
Sample ID Age Sex Symptoms 
Severity 
index 
GeneXpert Characterization 1 
Rybotype Spore count 
in stool 
(spore/g) 
Toxin 
production 
Antibiotic 
Susceptibility 
Toxin B 
Binary 
toxin 
TcdC tpi Tox A Tox B Tox Adel CM VA MZ CI 
CDST0317 66 F S 1 + - - + + + - 020 258667 8.441284272 R S R R 
CDST0404 74 M A 0 + - - + + + - 056 417234 10.35270557 R S R R 
CDST0466 21 F A 0 + - - + + + - 002 2169 8.0725346 R S R R 
CDST0498 76 F A 0 + - - + + + - 106 26150833 9.780703794 R S R R 
CDST0505 37 M A 0 + + - + + - - S2319 53249 7.867896464 R S R R 
CDST0529 72 F A 0 + - - + + + - 020 24492754 9.6043679 R S R R 
CDST0648 71 M S 1 + - - + + + - 001 1015873 10.5341083 R S R R 
CDST0674 60 M A 0 + - - + + + - NASD 126073 0 R S R R 
CDST0714 60 M A 0 - - - + + + - 012 12185185 6.314696526 R S R R 
CDST0915 86 M A 0 + - - + + + - 001 37202 10.61581353 R S R R 
CDST0920 92 M A 0 + - - + + + - 020 159504 10.60214209 R S R R 
CDST0949 68 F A 0 + - - + + + - Z 5870 7.8899602 R S R R 
CDST1055 66 M A 0 - - - + + + - O 13878 7.177917792 R S R R 
CDST1066 70 M A 0 - - - + + + - 020 32203 6.523561956 R S R R 
CDST1070 79 M A 0 - - - + - - - 046 110145 0 R S R R 
CDST1098 83 M S 2 + - - + + + - 174 2642857 10.24555271 R S R R 
CDST1120 52 F A 0 - - - + - - - S0367 287599 0 R S R R 
CDST1122 77 M A 0 + - - + + + - 020 63924 11.04957632 R S R R 
CDST1134 70 F A 0 + - - + - + + 017 2775362 0 R S R R 
